CA2560305C - Human anti-epidermal growth factor receptor antibody - Google Patents
Human anti-epidermal growth factor receptor antibody Download PDFInfo
- Publication number
- CA2560305C CA2560305C CA2560305A CA2560305A CA2560305C CA 2560305 C CA2560305 C CA 2560305C CA 2560305 A CA2560305 A CA 2560305A CA 2560305 A CA2560305 A CA 2560305A CA 2560305 C CA2560305 C CA 2560305C
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- tumor
- egfr
- antibody fragment
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940116977 epidermal growth factor Drugs 0.000 title description 27
- 102000009465 Growth Factor Receptors Human genes 0.000 title description 8
- 108010009202 Growth Factor Receptors Proteins 0.000 title description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 108
- 241000124008 Mammalia Species 0.000 claims abstract description 21
- 102000001301 EGF receptor Human genes 0.000 claims description 132
- 108060006698 EGF receptor Proteins 0.000 claims description 132
- 230000027455 binding Effects 0.000 claims description 57
- 238000011282 treatment Methods 0.000 claims description 38
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 36
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 36
- 239000002246 antineoplastic agent Substances 0.000 claims description 32
- 230000005764 inhibitory process Effects 0.000 claims description 29
- 230000004614 tumor growth Effects 0.000 claims description 26
- 239000003446 ligand Substances 0.000 claims description 24
- 229940034982 antineoplastic agent Drugs 0.000 claims description 22
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 18
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 18
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 230000026731 phosphorylation Effects 0.000 claims description 16
- 238000006366 phosphorylation reaction Methods 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 13
- 239000013604 expression vector Substances 0.000 claims description 11
- 229940127089 cytotoxic agent Drugs 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 230000004663 cell proliferation Effects 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 229960004768 irinotecan Drugs 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 4
- 230000030833 cell death Effects 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 16
- 201000010536 head and neck cancer Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 229940027941 immunoglobulin g Drugs 0.000 claims 1
- 230000024834 positive regulation of antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 25
- 230000004913 activation Effects 0.000 abstract description 22
- 201000010099 disease Diseases 0.000 abstract description 22
- 230000003463 hyperproliferative effect Effects 0.000 abstract description 17
- 241001465754 Metazoa Species 0.000 abstract description 12
- 239000003795 chemical substances by application Substances 0.000 abstract description 9
- 150000007523 nucleic acids Chemical class 0.000 abstract description 5
- 230000003472 neutralizing effect Effects 0.000 abstract description 4
- 108020004707 nucleic acids Proteins 0.000 abstract description 4
- 102000039446 nucleic acids Human genes 0.000 abstract description 4
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 abstract description 3
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 abstract description 3
- 102000045108 human EGFR Human genes 0.000 abstract description 3
- 102000018358 immunoglobulin Human genes 0.000 abstract description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 2
- 229940072221 immunoglobulins Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 95
- 239000012634 fragment Substances 0.000 description 55
- 108090000623 proteins and genes Proteins 0.000 description 45
- 230000014509 gene expression Effects 0.000 description 34
- 102000005962 receptors Human genes 0.000 description 26
- 108020003175 receptors Proteins 0.000 description 26
- 102400001368 Epidermal growth factor Human genes 0.000 description 25
- 101800003838 Epidermal growth factor Proteins 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 235000018102 proteins Nutrition 0.000 description 21
- 239000000427 antigen Substances 0.000 description 20
- 108091007433 antigens Proteins 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 19
- 239000013598 vector Substances 0.000 description 17
- 201000004681 Psoriasis Diseases 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 16
- 210000004881 tumor cell Anatomy 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 150000003384 small molecules Chemical class 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 13
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 13
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 13
- 229940122558 EGFR antagonist Drugs 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 230000033115 angiogenesis Effects 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 230000019491 signal transduction Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 11
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 11
- 239000005557 antagonist Substances 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 206010027476 Metastases Diseases 0.000 description 10
- 108010017622 Somatomedin Receptors Proteins 0.000 description 10
- 102000004584 Somatomedin Receptors Human genes 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 241000699660 Mus musculus Species 0.000 description 8
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 8
- -1 glucose or lactose) Chemical class 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 238000011580 nude mouse model Methods 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 238000002823 phage display Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 229960005395 cetuximab Drugs 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 229940044551 receptor antagonist Drugs 0.000 description 6
- 239000002464 receptor antagonist Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 5
- 208000005623 Carcinogenesis Diseases 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 5
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 5
- 108010025020 Nerve Growth Factor Proteins 0.000 description 5
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 5
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 230000036952 cancer formation Effects 0.000 description 5
- 231100000504 carcinogenesis Toxicity 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 5
- 229940126864 fibroblast growth factor Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 208000005017 glioblastoma Diseases 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 229940053128 nerve growth factor Drugs 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 108091006629 SLC13A2 Proteins 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000035578 autophosphorylation Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 208000037841 lung tumor Diseases 0.000 description 4
- 230000001613 neoplastic effect Effects 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 108090001008 Avidin Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 206010037575 Pustular psoriasis Diseases 0.000 description 3
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 3
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010923 batch production Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000007783 downstream signaling Effects 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229940121647 egfr inhibitor Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical group C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 102000005396 glutamine synthetase Human genes 0.000 description 3
- 108020002326 glutamine synthetase Proteins 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010015278 Erythrodermic psoriasis Diseases 0.000 description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 description 2
- 101001083798 Homo sapiens Hepatoma-derived growth factor Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 229940126049 IMC-1 Drugs 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 201000007455 central nervous system cancer Diseases 0.000 description 2
- 208000025997 central nervous system neoplasm Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 208000018554 digestive system carcinoma Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 201000002222 hemangioblastoma Diseases 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Chemical class 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000017066 negative regulation of growth Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 150000002902 organometallic compounds Chemical class 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000003566 phosphorylation assay Methods 0.000 description 2
- 238000001126 phototherapy Methods 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000017363 positive regulation of growth Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940120982 tarceva Drugs 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000013076 thyroid tumor Diseases 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003860 topical agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 206010055031 vascular neoplasm Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- RONQPWQYDRPRGG-UHFFFAOYSA-N 5,6-bis(4-fluoroanilino)isoindole-1,3-dione Chemical compound C1=CC(F)=CC=C1NC(C(=C1)NC=2C=CC(F)=CC=2)=CC2=C1C(=O)NC2=O RONQPWQYDRPRGG-UHFFFAOYSA-N 0.000 description 1
- VASKZFMOJFLZDZ-UHFFFAOYSA-N 5-phenyl-1h-tetrazol-1-ium;bromide Chemical compound [Br-].[NH2+]1N=NN=C1C1=CC=CC=C1 VASKZFMOJFLZDZ-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100038778 Amphiregulin Human genes 0.000 description 1
- 108010033760 Amphiregulin Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 102400001242 Betacellulin Human genes 0.000 description 1
- 101800001382 Betacellulin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000052052 Casein Kinase II Human genes 0.000 description 1
- 108010010919 Casein Kinase II Proteins 0.000 description 1
- 229920002157 Cellulin Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000630627 Diodella Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- MCAHMSDENAOJFZ-UHFFFAOYSA-N Herbimycin A Natural products N1C(=O)C(C)=CC=CC(OC)C(OC(N)=O)C(C)=CC(C)C(OC)C(OC)CC(C)C(OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-UHFFFAOYSA-N 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001110286 Homo sapiens Ras-related C3 botulinum toxin substrate 1 Proteins 0.000 description 1
- 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000013355 Mycteroperca interstitialis Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 102400001093 PAK-2p27 Human genes 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000036822 Small cell carcinoma of the ovary Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- IUHFWCGCSVTMPG-UHFFFAOYSA-N [C].[C] Chemical group [C].[C] IUHFWCGCSVTMPG-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 108700021358 erbB-1 Genes Proteins 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- SIHZWGODIRRSRA-ONEGZZNKSA-N erbstatin Chemical compound OC1=CC=C(O)C(\C=C\NC=O)=C1 SIHZWGODIRRSRA-ONEGZZNKSA-N 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002710 external beam radiation therapy Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- MCAHMSDENAOJFZ-BVXDHVRPSA-N herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000000504 luminescence detection Methods 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000005292 ovarian small cell carcinoma Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 206010033898 parapsoriasis Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229940066779 peptones Drugs 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 201000010914 pustulosis of palm and sole Diseases 0.000 description 1
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 description 1
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000034932 regulation of DNA biosynthetic process Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 101150108727 trpl gene Proteins 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides a fully human antibody that binds human EGFR
with affinity comparable to or higher than IMC-C225, and that neutralizes activation of EGFR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chains antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells and animals that encode and express these antibodies. The invention further provides a method for neutralizing activation of EGFR, treating in a mammal with neoplastic growth and non-cancerous hyperproliferative diseases using the antibodies alone or in combination with other agents.
with affinity comparable to or higher than IMC-C225, and that neutralizes activation of EGFR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chains antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells and animals that encode and express these antibodies. The invention further provides a method for neutralizing activation of EGFR, treating in a mammal with neoplastic growth and non-cancerous hyperproliferative diseases using the antibodies alone or in combination with other agents.
Description
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.
NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
NOTE: For additional volumes please contact the Canadian Patent Office.
HUMAN ANTI-EPIDERMAL GROWTH FACTOR
RECEPTOR ANTIBODY
FIELD OF THE INVENTION
[0001] The present invention is directed to monoclonal antibodies that are specific the epidermal growth factor receptor (EGFR). These antibodies can be used in treating neoplastic diseases and hyperproliferative disorders, among others.
BACKGROUND OF THE INVENTION
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.
NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
NOTE: For additional volumes please contact the Canadian Patent Office.
HUMAN ANTI-EPIDERMAL GROWTH FACTOR
RECEPTOR ANTIBODY
FIELD OF THE INVENTION
[0001] The present invention is directed to monoclonal antibodies that are specific the epidermal growth factor receptor (EGFR). These antibodies can be used in treating neoplastic diseases and hyperproliferative disorders, among others.
BACKGROUND OF THE INVENTION
[0002] Although normal cells proliferate by the highly controlled activation of growth factor receptor tyrosine kinases (RTKs) by their respective ligands, cancer cells also proliferate by the activation of growth factor receptors, but lose the careful control of normal proliferation. The loss of control may be caused by numerous factors, such as the overexpression of growth factors and/or receptors, and autonomous activation of biochemical pathways regulated by growth factors. Some examples of RTKs involved in tumorigenesis are the receptors for epidermal growth factor (EGFR), platelet-derived growth factor (PDGFR), insulin-like growth factor (IGFR), nerve growth factor (NGFR), and fibroblast growth factor (FGF). Binding of these growth factors to their cell surface receptors induces receptor activation, which initiates and modifies signal transduction pathways and leads to cell proliferation and differentiation.
[0003] Members of the epidermal growth factor (EGF) receptor family are particularly important growth factor receptor tyrosine kinases associated with tumorigenesis of epidermal cells. The first member of the EGF receptor family to be discovered was EGFR, which is expressed on many types of tumor cells. EGFR has been found to be involved in regulation of tumor cell division and growth, repair and survival, angiogenesis, invasion and tumor metastasis.
[0004] EGFR is a 170 IcD membrane-spanning glycoprotein with an extracellular ligand binding domain, a transmembrane region and a cytoplasmic protein tyrosine kinase domain. Examples of ligands that stimulate EGFR include epidermal growth factor (EGF), transforming growth factor-a (TGF-a), heparin-binding growth factor (HBGF), 13-cellulin, and Cripto-1. Binding of specific ligands results in EGFR
autophosphorylation, activation of the receptor's cytoplasmic tyrosine kinase domain and initiation of multiple signal transduction pathways that regulate tumor growth and survival. The EGFR pathway also influences production of various other angiogenic factors, such as VEGF and basis fibroblastic growth factor (bFGF), in tumors.
autophosphorylation, activation of the receptor's cytoplasmic tyrosine kinase domain and initiation of multiple signal transduction pathways that regulate tumor growth and survival. The EGFR pathway also influences production of various other angiogenic factors, such as VEGF and basis fibroblastic growth factor (bFGF), in tumors.
[0005] Growth factors that activate EGFR are also thought to play a role in tumor angiogenesis. Angio genesis, which refers to the formation of capillaries from pre-existing vessels in the embryo and adult organism, is known to be a key element in tumor growth, survival and metastasis. It has been reported that EGFR mediated stimulation of tumor cells leads to increased expression of the angiogenic factors vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), and basic fibroblast growth factor (bFGF), which can lead to activation of tumor-associated vascular endothelial cells. Stimulation of tumor-associated vascular endothelial cells may also occur through activation of their own EGF
receptors, by tumor produced growth factors such as TGF-a and EGF.
receptors, by tumor produced growth factors such as TGF-a and EGF.
[0006] It has been reported that many human tumors express or overexpress EGFR. Expression of EGFR is correlated with poor prognosis, decreased survival, and/or increased metastasis. EGFR, because of this involvement in tumorigenesis, has been specifically targeted for anticancer therapies. These therapies have predominantly included either a monoclonal antibody that blocks binding of ligand to the extracellular domain of the receptor or a synthetic tyrosine kinase inhibitor that acts directly on the intracellular region to prevent signal transduction.
[0007] For example, Cetuximab MAb (ERBITUX ) is a recombinant, human/mouse chimeric, monoclonal antibody that binds specifically to the extracellular domain of the human EGFR. Cetuximab is an EGFR antagonist, which blocks ligand binding to EGFR, prevents receptor activation, and inhibits growth of tumor cells that express EGFR. Cetuximab has been approved for use in combination with or without irinotecan in the treatment of patients with epidermal growth factor receptor-expressing, metastatic colorectal cancer who are refractory or can not tolerate irinotecan-based chemotherapy. Cetuximab has also been shown to be effective for treatment of psoriasis.
SUMMARY OF THE INVENTION
SUMMARY OF THE INVENTION
[0008] The present invention provides monoclonal antibodies or fragments thereof specific for EGFR, preferably the extracellular region of EGFR, comprising anywhere from one to six complementarity determining regions (CDRs) selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO;6, SEQ ID NO:10, SEQ ID
NO:12, and SEQ ID NO:14. Preferably, the antibodies are human. More preferably, the antibodies of the present invention, or fragments thereof, comprise SEQ ID
NO:2, SEQ ID
NO:4, and SEQ ID NO:6. Alternatively, but also preferably, the antibodies of the present invention, or fragments thereof, comprise SEQ ID NO:10, SEQ ID NO:12, and SEQ
ID
NO:14. More preferably the antibodies of the present invention, or fragments thereof, comprise a heavy chain variable region of SEQ ID NO:8 and/or a light chain variable region of SEQ ID NO:16. Such antibodies or fragments thereof of the present invention have various properties, including the ability to neutralize EGFR and prevent binding of a ligand of EGFR to its receptor.
NO:12, and SEQ ID NO:14. Preferably, the antibodies are human. More preferably, the antibodies of the present invention, or fragments thereof, comprise SEQ ID
NO:2, SEQ ID
NO:4, and SEQ ID NO:6. Alternatively, but also preferably, the antibodies of the present invention, or fragments thereof, comprise SEQ ID NO:10, SEQ ID NO:12, and SEQ
ID
NO:14. More preferably the antibodies of the present invention, or fragments thereof, comprise a heavy chain variable region of SEQ ID NO:8 and/or a light chain variable region of SEQ ID NO:16. Such antibodies or fragments thereof of the present invention have various properties, including the ability to neutralize EGFR and prevent binding of a ligand of EGFR to its receptor.
[0009] Additionally, the present invention provides isolated polynucleotides encoding the present antibodies or fragments thereof as well as expression vectors comprising these polynucleotide sequences operably linked to an expression sequence.
Recombinant host cells comprising the expression vector, or a progeny thereof, wherein the cell expresses the present antibodies or fragments thereof are also provided. Methods are also provided for producing antibodies or fragments thereof comprising culturing these cells under conditions permitting expression of the antibodies or fragments thereof. The antibodies or fragments thereof can then be purified from the cell or medium of the cell.
Recombinant host cells comprising the expression vector, or a progeny thereof, wherein the cell expresses the present antibodies or fragments thereof are also provided. Methods are also provided for producing antibodies or fragments thereof comprising culturing these cells under conditions permitting expression of the antibodies or fragments thereof. The antibodies or fragments thereof can then be purified from the cell or medium of the cell.
[0010] Also, the present invention provides methods of treating tumor growth in a mammal, comprising administering to the mammal an effective amount of a present antibody. The present antibodies can be coadministered with antibodies that bind to other RTKs. The methods can also comprise administering to the mammal an anti-neoplastic agent or treatment, including, for example, a chemotherapeutic agent and/or radiation. In certain embodiments, tumor growth is inhibited. In preferred embodiments, treatment results in tumor regression.
[0011] The present invention also provides methods of treating a non-cancer hyperproliferative disease, e.g., psoriasis, in a mammal comprising administering to the mammal an effective amount of the present antibody.
BRIEF DESCRIPTION OF THE FIGURES
BRIEF DESCRIPTION OF THE FIGURES
[0012] Figures 1A and 1B shows the cloning vectors for expression of immunoglobulin genes, pDFC and pEE12.1L. Figure 1C shows the resulting single full human anti-EGFR antibody containing vector plasmid, pGS-11F8.
[0013] Figure 2 shows the restriction digest profile of pGS-11F8. DNA size markers are indicated in the DNA ladder as kilobase pairs.
[0014] Figure 3 shows in-vitro binding of IMC-C11F8 and IMC-C225 to EGFR as measured by ELISA.
[0015] Figure 4 shows in vitro competition results of IMC-11F8 and IMC-C225 with 125I-labeled EGF for EGFR binding.
[0016] Figure 5 shows effects of IMC-11F8 and IMC-C225 on the phosphorylation of EGFR in BxPC3 cells. Control antibody used is IMC-1C11.
[0017] Figure 6 shows inhibition of EGFR phosphorylation by IMC-11F8 and IMC-C225 in A431 cells.
[0018] Figure 7 shows Western Blot analysis of EGFR phosphorylation in the presence of unstimulated control cells (lane 1), EGF (lane 2), IMC-C225 (lane 3), IMC-11F8 (lane 4) and control antibody (lane 5). Figure 5A shows phosphorylated EGFR
using an anti-phosphotyrosine antibody and Figure 5B shows total EGFR in the stimulated cells.
using an anti-phosphotyrosine antibody and Figure 5B shows total EGFR in the stimulated cells.
[0019] Figure 8 shows inhibition of EGF-stimulated EGFR phosphorylation by various concentrations of IMC-11F8. Figure 8A shows anti-phosphotyrosine antibody Western blot analysis of EGFR in unstimulated control cells (lane 1), stimulated cells treated with no IMC-11F8 antibody (lane 2), 15Iug/mL (lane 3), 3 ps/mL (lane 4), and 0.6 lug/mL (lane 3) IMC-11F8. Figure 8B shows total EGFR.
[0020] Figure 9 shows inhibition of DWi cell proliferation by IMC-11F8, IMC-C225 and control antibody, IMC-ICII as assessed by an MIT assay.
[0021] Figure 10 shows the specific lysis of 51Cr-labeled DiFi cells treated with IMC-11F8 or IMC-C225 (ERBITUXe).
[0022] Figure 11 shows the growth of A43 I tumor cells in mice treated with either IMC-11F8 or IMC-C225 (Cetuximab). Untreated animals served as controls for tumor growth.
[0023] Figure 12 shows the growth of BxPC3 tumor cells in mice treated with either INIC-11F8 or IMC-C225 (Cetuximab). Untreated animals served as controls for tumor growth.
[0024] Figure 13 shows immunohistochemical staining of xenografted human tumors from nude mice treated with saline or IMC-l1F8. Panel A and B, A431 xenografts from nude mice treated with saline (A) or IMC-11F8 (B). Panel C and D, BxPC3 xenografts from nude mice treated with saline (C) or IMC-11F8 (D). Panel B and F, Ki-67 staining of A413 xenografts from nude mice treated with saline (E) or IMC-1 IFS (F).
[0025] Figure 14 shows inhibition of xenografted human colorectal carcinomas in nude mice by IMC-11F8 in combination with CPT-11. Nude mice bearing human colorectal tumor xenografts GEO (panel A), DLD-1 (panel B), or HT-29 (panel C), treated by intraperitoneal injection with saline or IMC-11F8 twice a week at 0.3 mg or 1.0 mg/injection, alone or in combination with CPT-11 at the dose of 100 rng/kg once a week.
Tumor sizes were measured twice a week. Data represent the mean + SE of tumor measurements from 10 animals in each group. (I)) Tumor regression upon treatment with 11/1C-11F8 alone or in combination with CPT-11. Each treatment group consists tumor-bearing animals.
DETAILED DESCRIPTION OF THE INVENTION
Tumor sizes were measured twice a week. Data represent the mean + SE of tumor measurements from 10 animals in each group. (I)) Tumor regression upon treatment with 11/1C-11F8 alone or in combination with CPT-11. Each treatment group consists tumor-bearing animals.
DETAILED DESCRIPTION OF THE INVENTION
[0026] The present invention provides monoclonal antibodies and fragments thereof that are specific for ECM, as well as isolated or purified polynucleotide sequences encoding the antibodies. Antibodies of the present invention are preferably human and can be used to treat neoplastic diseases, including solid and non-solid tumors and for treatment of hyperproliferative disorders.
[0027] Naturally occurring antibodies typically have two identical heavy chains and two identical light chains, with each light chain covalently linked to a heavy chain by an interchain disulfide bond and multiple disulfide bonds further link the two heavy chains to one another. Individual chains can fold into domains having similar sizes (110-125 amino acids) and structures, but different functions. The light chain can comprise one variable domain (VL) and/or one constant domain (CL). The heavy chain can also comprise one variable domain (VH) and/or, depending on the class or isotype of antibody, three or four constant domains (CH1, CH 2, CH3 and CH4). In humans, the isotypes are IgA, IgD, IgE, IgG, and IgM, with IgA and IgG further subdivided into subclasses or subtypes (IgA1.2 and IgG1-4.
[0028] Generally, the variable domains show considerable amino acid sequence variability from one antibody to the next, particularly at the location of the antigen-binding site. Three regions, called hypervariable or complementarity-determining regions (CDRs), are found in each of VL and VH, which are supported by less variable regions called framework variable regions.
[0029] The portion of an antibody consisting of VL and VH domains is designated Fv (fragment variable) and constitutes the antigen-binding site. Single chain Fv (scFv) is an antibody fragment containing a VL domain and a VH domain on one polypeptide chain, wherein the N terminus of one domain and the C terminus of the other domain are joined by a flexible linker (see, e.g., U.S. Pat. No. 4,946,778 (Ladner et al.); WO
88/09344, (Huston et al.). WO 92/01047 (McCafferty et al.) describes the display of scFv fragments on the surface of soluble recombinant genetic display packages, such as bacteriophage.
88/09344, (Huston et al.). WO 92/01047 (McCafferty et al.) describes the display of scFv fragments on the surface of soluble recombinant genetic display packages, such as bacteriophage.
[0030] The peptide linkers used to produce the single chain antibodies can be flexible peptides selected to assure that the proper three-dimensional folding of the VL and VH domains occurs. The linker is generally 10 to 50 amino acid residues.
Preferably, the linker is 10 to 30 amino acid residues. More preferably the linker is 12 to 30 amino acid residues. Most preferably is a linker of 15 to 25 amino acid residues. An example of such linker peptides includes (Gly-Gly-Gly-Gly-Ser)3 (SEQ ID NO:19).
Preferably, the linker is 10 to 30 amino acid residues. More preferably the linker is 12 to 30 amino acid residues. Most preferably is a linker of 15 to 25 amino acid residues. An example of such linker peptides includes (Gly-Gly-Gly-Gly-Ser)3 (SEQ ID NO:19).
[0031] Single chain antibodies lack some or all of the constant domains of the whole antibodies from which they are derived. Therefore, they can overcome some of the problems associated with the use of whole antibodies. For example, single-chain antibodies tend to be free of certain undesired interactions between heavy-chain constant regions and other biological molecules. Additionally, single-chain antibodies are considerably smaller than whole antibodies and can have greater permeability than whole antibodies, allowing single-chain antibodies to localize and bind to target antigen-binding sites more efficiently. Furthermore, the relatively small size of single-chain antibodies makes them less likely to provoke an unwanted immune response in a recipient than whole antibodies.
[0032] Multiple single chain antibodies, each single chain having one VH and one VL domain covalently linked by a first peptide linker, can be covalently linked by at least one or more peptide linker to form a multivalent single chain antibodies, which can be monospecific or multispecific. Each chain of a multivalent single chain antibody includes a variable light chain fragment and a variable heavy chain fragment, and is linked by a peptide linker to at least one other chain. The peptide linker is composed of at least fifteen amino acid residues. The maximum number of amino acid residues is about one hundred.
[0033] Two single chain antibodies can be combined to form a diabody, also known as a bivalent dimer. Diabodies have two chains and two binding sites, and can be monospecific or bispecific. Each chain of the diabody includes a VH domain connected to a VL domain. The domains are connected with linkers that are short enough to prevent pairing between domains on the same chain, thus driving the pairing between complementary domains on different chains to recreate the two antigen-binding sites.
[0034] Three single chain antibodies can be combined to form triabodies, also known as trivalent trimers. Triabodies are constructed with the amino acid terminus of a VL or VH domain directly fused to the carboxyl terminus of a VL or VH domain, i.e., without any linker sequence. The triabody has three Fv heads with the polypeptides arranged in a cyclic, head-to-tail fashion. A possible conformation of the triabody is planar with the three binding sites located in a plane at an angle of 120 degrees from one another. Triabodies can be monospecific, bispecific or trispecific.
[0035] Fab (Fragment, antigen binding) refers to the fragments of the antibody consisting of VL CL VH and CH1 domains. Those generated following papain digestion simply are referred to as Fab and do not retain the heavy chain hinge region.
Following pepsin digestion, various Fabs retaining the heavy chain hinge are generated.
Those divalent fragments with the interchain disulfide bonds intact are referred to as F(ab')2, while a monovalent Fab' results when the disulfide bonds are not retained.
F(ab')2 fragments have higher avidity for antigen that the monovalent Fab fragments.
Following pepsin digestion, various Fabs retaining the heavy chain hinge are generated.
Those divalent fragments with the interchain disulfide bonds intact are referred to as F(ab')2, while a monovalent Fab' results when the disulfide bonds are not retained.
F(ab')2 fragments have higher avidity for antigen that the monovalent Fab fragments.
[0036] Fc (Fragment crystallization) is the designation for the portion or fragment of an antibody that comprises paired heavy chain constant domains. In an IgG
antibody, for example, the Fc comprises CH2 and CH3 domains. The Fc of an IgA or an IgM
antibody further comprises a CH4 domain. The Fc is associated with Fc receptor binding, activation of complement-mediated cytotoxicity and antibody-dependent cellular-cytoxicity (ADCC). For antibodies such as IgA and IgM, which are complexes of multiple IgG like proteins, complex formation requires Fc constant domains.
antibody, for example, the Fc comprises CH2 and CH3 domains. The Fc of an IgA or an IgM
antibody further comprises a CH4 domain. The Fc is associated with Fc receptor binding, activation of complement-mediated cytotoxicity and antibody-dependent cellular-cytoxicity (ADCC). For antibodies such as IgA and IgM, which are complexes of multiple IgG like proteins, complex formation requires Fc constant domains.
[0037] Finally, the hinge region separates the Fab and Fc portions of the antibody, providing for mobility of Fabs relative to each other and relative to Fc, as well as including multiple disulfide bonds for covalent linkage of the two heavy chains.
[0038] Thus, antibodies of the invention include, but are not limited to, naturally occurring antibodies, bivalent fragments such as (Fab')2, monovalent fragments such as Fab, single chain antibodies, single chain Fv (scFv), single domain antibodies, multivalent single chain antibodies, diabodies, triabodies, and the like that bind specifically with antigens.
[0039] The antibodies, or fragments thereof, of the present invention are specific for EGFR. Antibody specificity refers to selective recognition of the antibody for a particular epitope of an antigen. Antibodies, or fragments thereof, of the present invention, for example, can be monospecific or bispecific. Bispecific antibodies (BsAbs) are antibodies that have two different antigen-binding specificities or sites.
Where an antibody has more than one specificity, the recognized epitopes can be associated with a single antigen or with more than one antigen. Thus, the present invention provides bispecific antibodies, or fragments thereof, that bind to two different antigens, with at least one specificity for EGFR.
Where an antibody has more than one specificity, the recognized epitopes can be associated with a single antigen or with more than one antigen. Thus, the present invention provides bispecific antibodies, or fragments thereof, that bind to two different antigens, with at least one specificity for EGFR.
[0040] Specificity of the present antibodies, or fragments thereof, for EGFR can be determined based on affinity and/or avidity. Affinity, represented by the equilibrium constant for the dissociation of an antigen with an antibody (Kd), measures the binding strength between an antigenic determinant and an antibody-binding site.
Avidity is the measure of the strength of binding between an antibody with its antigen.
Avidity is related to both the affinity between an epitope with its antigen binding site on the antibody, and the valence of the antibody, which refers to the number of antigen binding sites of a particular epitope. Antibodies typically bind with a dissociation constant (Kd) of le to 10-11 liters/mol. Any Kd less than 10-4 liters/mol is generally considered to indicate nonspecific binding. The lesser the value of the Kd, the stronger the binding strength between an antigenic determinant and the antibody binding site.
Avidity is the measure of the strength of binding between an antibody with its antigen.
Avidity is related to both the affinity between an epitope with its antigen binding site on the antibody, and the valence of the antibody, which refers to the number of antigen binding sites of a particular epitope. Antibodies typically bind with a dissociation constant (Kd) of le to 10-11 liters/mol. Any Kd less than 10-4 liters/mol is generally considered to indicate nonspecific binding. The lesser the value of the Kd, the stronger the binding strength between an antigenic determinant and the antibody binding site.
[0041] As used herein, "antibodies" and "antibody fragments" includes modifications that retain specificity for the EGF receptor. Such modifications include, but are not limited to, conjugation to an effector molecule such as a chemotherapeutic agent (e.g., cisplatin, taxol, doxorubicin) or cytotoxin (e.g., a protein, or a non-protein organic chemotherapeutic agent). The antibodies can be modified by conjugation to detectable reporter moieties. Also included are antibodies with alterations that affect non-binding characteristics such as half-life (e.g., pegylation).
[0042] Proteins and non-protein agents may be conjugated to the antibodies by methods that are known in the art. Conjugation methods include direct linkage, linkage via covalently attached linkers, and specific binding pair members (e.g., avidin-biotin).
Such methods include, for example, that described by Greenfield et al., Cancer Research 50, 6600-6607 (1990) for the conjugation of doxorubicin and those described by Amon et al., Adv. Exp. Med. Biol. 303, 79-90 (1991) and by Kiseleva et al., Mol. Biol.
(USSR)25, 508-514 (1991) for the conjugation of platinum compounds.
Such methods include, for example, that described by Greenfield et al., Cancer Research 50, 6600-6607 (1990) for the conjugation of doxorubicin and those described by Amon et al., Adv. Exp. Med. Biol. 303, 79-90 (1991) and by Kiseleva et al., Mol. Biol.
(USSR)25, 508-514 (1991) for the conjugation of platinum compounds.
[0043] Equivalents of the antibodies, or fragments thereof, of the present invention also include polypeptides with amino acid sequences substantially the same as the amino acid sequence of the variable or hypervariable regions of the full-length anti-EGFR
antibodies disclosed herein. Substantially the same amino acid sequence is defined herein as a sequence with at least about 70%, preferably at least about 80%, and more preferably at least about 90% homology, as determined by the FASTA search method in accordance with Pearson and Lipman (Proc. Natl. Acad. Sci. USA 85, 2444-8 (1988)), including sequences that are at least about 70%, preferably at least about 80%, and more preferably at least about 90% identical.
antibodies disclosed herein. Substantially the same amino acid sequence is defined herein as a sequence with at least about 70%, preferably at least about 80%, and more preferably at least about 90% homology, as determined by the FASTA search method in accordance with Pearson and Lipman (Proc. Natl. Acad. Sci. USA 85, 2444-8 (1988)), including sequences that are at least about 70%, preferably at least about 80%, and more preferably at least about 90% identical.
[0044] Such antibodies will have the same or similar binding, ligand blocking, and receptor neutralizing activities to antibodies of the invention that comprise SEQ ID NOS:8 and 16, particularly where there are conservative amino acid substitutions. A
conservative amino acid substitution is defined as a change in the amino acid composition by way of changing one or more amino acids of a peptide, polypeptide or protein, or fragment thereof. The substitution is of amino acids with generally similar properties (e.g., acidic, basic, aromatic, size, positively or negatively charged, polarity, non-polarity) such that the substitutions do not substantially alter relevant peptide, polypeptide or protein characteristics (e.g., charge, isoelectric point, affinity, avidity, conformation, solubility) or activity. Typical conservative substitutions are selected within groups of amino acids, which groups include, but are not limited to:
(1) hydrophobic: methionine (M), alanine (A), valine (V), leucine (L), isoleucine (I);
(2) hydrophilic: cysteine (C), serine (S), threonine (T), asparagine (N), glutamine (Q);
(3) acidic: aspartic acid (D), glutamic acid (E);
(4) basic: histidine (H), lysine (K), arginine (R);
(5) aromatic: phenylalanine (F), tyrosine (Y) and tryptophan (W);
(6) residues that influence chain orientation: gly, pro.
conservative amino acid substitution is defined as a change in the amino acid composition by way of changing one or more amino acids of a peptide, polypeptide or protein, or fragment thereof. The substitution is of amino acids with generally similar properties (e.g., acidic, basic, aromatic, size, positively or negatively charged, polarity, non-polarity) such that the substitutions do not substantially alter relevant peptide, polypeptide or protein characteristics (e.g., charge, isoelectric point, affinity, avidity, conformation, solubility) or activity. Typical conservative substitutions are selected within groups of amino acids, which groups include, but are not limited to:
(1) hydrophobic: methionine (M), alanine (A), valine (V), leucine (L), isoleucine (I);
(2) hydrophilic: cysteine (C), serine (S), threonine (T), asparagine (N), glutamine (Q);
(3) acidic: aspartic acid (D), glutamic acid (E);
(4) basic: histidine (H), lysine (K), arginine (R);
(5) aromatic: phenylalanine (F), tyrosine (Y) and tryptophan (W);
(6) residues that influence chain orientation: gly, pro.
[0045] Antibodies of the present invention further include those for which binding characteristics have been improved by direct mutation, methods of affinity maturation, phage display, or chain shuffling. Affinity and specificity can be modified or improved by mutating CDRs and screening for antigen binding sites having the desired characteristics (see, e.g., Yang et al., J. Mol. Biol., 254: 392-403 (1995)). CDRs are mutated in a variety of ways. One way is to randomize individual residues or combinations of residues so that in a population of, otherwise identical antigen binding sites, all twenty amino acids are found at particular positions. Alternatively, mutations are induced over a range of CDR
residues by error prone PCR methods (see, e.g., Hawkins et al., J. Mol. Biol., 226: 889-896 (1992)). For example, phage display vectors containing heavy and light chain variable region genes can be propagated in mutator strains of E. coli (see, e.g., Low et al., J. Mol. Biol., 250: 359-368 (1996)). These methods of mutagenesis are illustrative of the many methods known to one of skill in the art.
residues by error prone PCR methods (see, e.g., Hawkins et al., J. Mol. Biol., 226: 889-896 (1992)). For example, phage display vectors containing heavy and light chain variable region genes can be propagated in mutator strains of E. coli (see, e.g., Low et al., J. Mol. Biol., 250: 359-368 (1996)). These methods of mutagenesis are illustrative of the many methods known to one of skill in the art.
[0046] Each domain of the antibodies of this invention can be a complete immunoglobulin domain (e.g., a heavy or light chain variable or constant domain), or it can be a functional equivalent or a mutant or derivative of a naturally-occurring domain, or a synthetic domain constructed, for example, in vitro using a technique such as one described in WO 93/11236 (Griffiths et al.). For instance, it is possible to join together domains corresponding to antibody variable domains, which are missing at least one amino acid. The important characterizing feature of the antibodies is the presence of an antigen binding site. The terms variable heavy and light chain fragment should not be construed to exclude variants that do not have a material effect on specificity.
[0047] The antibodies of the present invention, or fragments thereof, are human antibodies having one, two, three, four, five, and/or six complementarity determining regions (CDRs) selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ
ID NO:6, SEQ ID NO:10, SEQ ID NO:12, and SEQ ID NO:14. Preferably, the antibodies (or fragments thereof) of the present invention have CDRs of SEQ NO:2, SEQ JD
NO:4 and SEQ ID NO:6. Alternatively and also preferably, the present antibodies, or fragments thereof, have CDRs of SEQ ID NO:10, SEQ ID NO:12 and SEQ ID NO:14.
The amino acid sequences of the CDRs are set forth below in Table 1.
Heavy Chain CDR1 SGDYYWS SEQ ID NO:2 CDR2 YIYYSGSTDYNPSLKS SEQ ID NO:4 CDR3 VSIFGVGTFDY SEQ ID NO:6 Light Chain CDR1 RASQSVSSYLA SEQ ID NO:10 CDR2 DASNRAT SEQ ID NO:12 CDR3 HQYGSTPLT SEQ ID NO:14
ID NO:6, SEQ ID NO:10, SEQ ID NO:12, and SEQ ID NO:14. Preferably, the antibodies (or fragments thereof) of the present invention have CDRs of SEQ NO:2, SEQ JD
NO:4 and SEQ ID NO:6. Alternatively and also preferably, the present antibodies, or fragments thereof, have CDRs of SEQ ID NO:10, SEQ ID NO:12 and SEQ ID NO:14.
The amino acid sequences of the CDRs are set forth below in Table 1.
Heavy Chain CDR1 SGDYYWS SEQ ID NO:2 CDR2 YIYYSGSTDYNPSLKS SEQ ID NO:4 CDR3 VSIFGVGTFDY SEQ ID NO:6 Light Chain CDR1 RASQSVSSYLA SEQ ID NO:10 CDR2 DASNRAT SEQ ID NO:12 CDR3 HQYGSTPLT SEQ ID NO:14
[0048] In another embodiment, the present antibodies, or fragments thereof, can have a heavy chain variable region of SEQ ID NO:8 and/or a light chain variable region of SEQ ID NO:16. IMC-11F8 is a particularly preferred antibody of the present invention.
This antibody has human VH and VL framework regions (FWs) as well as CDRs. The VH
variable domain of IMC-11F8 (SEQ ID NO:8) has three CDRs (SEQ ID NOS:2, 4, and 6) and four FWs and the VL domain (SEQ BD NO:16) has three CDRs (SEQ ID NOS:10, 12, and 14) and four FWs.
This antibody has human VH and VL framework regions (FWs) as well as CDRs. The VH
variable domain of IMC-11F8 (SEQ ID NO:8) has three CDRs (SEQ ID NOS:2, 4, and 6) and four FWs and the VL domain (SEQ BD NO:16) has three CDRs (SEQ ID NOS:10, 12, and 14) and four FWs.
[0049] Preferably, the antibodies, or fragments thereof, of the present invention neutralize EGFR. Binding of a ligand, e.g., EGF or TGF-a, to an external, extracellular domain of EGFR stimulates receptor dimerization, autophosphorylation of EGFR, activation of the receptor's internal, cytoplasmic tyrosine kinase domain, and initiation of multiple signal transduction and transactivation pathways involved in regulation of DNA
synthesis (gene activation) and cell cycle progression or division. Also preferably, the anti-EGFR antibodies (or fragments thereof) of the present invention are specific for the extracellular region of EGFR. The present antibodies, or fragments thereof, further preferably prevent binding of a ligand of EGFR to its receptor. In this embodiment, the antibodies of the present invention, or fragments thereof, bind EGFR at least as strongly as the natural ligands of EGFR (EGF and TGF-a).
synthesis (gene activation) and cell cycle progression or division. Also preferably, the anti-EGFR antibodies (or fragments thereof) of the present invention are specific for the extracellular region of EGFR. The present antibodies, or fragments thereof, further preferably prevent binding of a ligand of EGFR to its receptor. In this embodiment, the antibodies of the present invention, or fragments thereof, bind EGFR at least as strongly as the natural ligands of EGFR (EGF and TGF-a).
[0050] Neutralization of EGFR includes inhibition, diminution, inactivation and/or disruption of one or more of these activities normally associated with signal transduction.
Thus, neutralizing EGFR has various effects, including inhibition, diminution, inactivation and/or disruption of growth (proliferation and differentiation), angiogenesis (blood vessel recruitment, invasion, and metastasis), and cell motility and metastasis (cell adhesion and invasiveness).
Thus, neutralizing EGFR has various effects, including inhibition, diminution, inactivation and/or disruption of growth (proliferation and differentiation), angiogenesis (blood vessel recruitment, invasion, and metastasis), and cell motility and metastasis (cell adhesion and invasiveness).
[0051] One measure of EGFR neutralization is inhibition of the tyrosine kinase activity of the receptor. Tyrosine kinase inhibition can be determined using well-known methods; for example, by measuring the autophosphorylation level of recombinant kinase receptor, and/or phosphorylation of natural or synthetic substrates. Thus, phosphorylation assays are useful in determining neutralizing antibodies in the context of the present invention. Phosphorylation can be detected, for example, using an antibody specific for phosphotyrosine in an ELISA assay or on a western blot. Some assays for tyrosine kinase activity are described in Panek et al., J. Pharmacol. Exp. Thera. 283: 1433-44 (1997)and Batley et al., Life Sci. 62: 143-50 (1998).
[0052] In addition, methods for detection of protein expression can be utilized to determine EGFR neutralization, wherein the proteins or protein activities or activation states being measured are regulated by EGFR tyrosine kinase activity. These methods include immunohistochemistry (IHC) for detection of protein expression, fluorescence in situ hybridization (FISH) for detection of gene amplification, competitive radioligand binding assays, solid matrix blotting techniques, such as Northern and Southern blots, reverse transcriptase polymerase chain reaction (RT-PCR) and ELISA. See, e.g., Grandis et al., Cancer, 78:1284-92 (1996); Shimizu et al., Japan J. Cancer Res., 85:567-71(1994);
Sauter et al., Am. J. Path., 148:1047-53 (1996); Collins, Glia, 15:289-96 (1995); Radinsky et al., Clin. Cancer Res., 1:19-31 (1995); Petrides et al., Cancer Res., 50:3934-39 (1990);
Hoffmann et al., Anticancer Res., 17:4419-26 (1997); Wikstrand et al., Cancer Res., 55:3140-48 (1995).
Sauter et al., Am. J. Path., 148:1047-53 (1996); Collins, Glia, 15:289-96 (1995); Radinsky et al., Clin. Cancer Res., 1:19-31 (1995); Petrides et al., Cancer Res., 50:3934-39 (1990);
Hoffmann et al., Anticancer Res., 17:4419-26 (1997); Wikstrand et al., Cancer Res., 55:3140-48 (1995).
[0053] In vivo assays can also be utilized to determine EGFR neutralization.
For example, receptor tyrosine kinase inhibition can be observed by mitogenic assays using cell lines stimulated with receptor ligand in the presence and absence of inhibitor. For example, A43 lcells (American Type Culture Collection (ATCC), Rockville, MD) stimulated with EGF can be used to assay EGFR inhibition. Another method involves testing for inhibition of growth of EGFR-expressing tumor cells, using for example, human tumor cells injected into a mouse. See, e.g., U.S. Patent No. 6,365,157 (Rockwell et al.).
For example, receptor tyrosine kinase inhibition can be observed by mitogenic assays using cell lines stimulated with receptor ligand in the presence and absence of inhibitor. For example, A43 lcells (American Type Culture Collection (ATCC), Rockville, MD) stimulated with EGF can be used to assay EGFR inhibition. Another method involves testing for inhibition of growth of EGFR-expressing tumor cells, using for example, human tumor cells injected into a mouse. See, e.g., U.S. Patent No. 6,365,157 (Rockwell et al.).
[0054] The present invention is not limited by any particular mechanism of EGFR
neutralization. The anti-EGFR antibodies of the present invention can bind externally to the EGF cell surface receptor, block binding of ligand (e.g., EGF or TGF-a) and subsequent signal transduction mediated via the receptor-associated tyrosine kinase, and prevent phosphorylation of the EGFR and other downstream proteins in the signal transduction cascade. The receptor-antibody complex can also be internalized and degraded, resulting in receptor cell surface downregulation. Matrix metalloproteinases, which function in tumor cell invasion and metastasis, can also be downregulated by the antibodies of the present invention. Moreover, antibodies of the present invention may exhibit inhibition of growth factor production and angiogenesis.
neutralization. The anti-EGFR antibodies of the present invention can bind externally to the EGF cell surface receptor, block binding of ligand (e.g., EGF or TGF-a) and subsequent signal transduction mediated via the receptor-associated tyrosine kinase, and prevent phosphorylation of the EGFR and other downstream proteins in the signal transduction cascade. The receptor-antibody complex can also be internalized and degraded, resulting in receptor cell surface downregulation. Matrix metalloproteinases, which function in tumor cell invasion and metastasis, can also be downregulated by the antibodies of the present invention. Moreover, antibodies of the present invention may exhibit inhibition of growth factor production and angiogenesis.
[0055] Antibody fragments can be produced by cleaving a whole antibody, or by expressing DNA that encodes the fragment. Fragments of antibodies may be prepared by methods described by Larnoyi et al., J. Immunol. Methods, 56: 235-243 (1983) and by Parham, ./. Inzmunol. 131: 2895-2902 (1983). Such fragments may contain one or both Fab fragments or the F(a1:02 fragment. Such fragments may also contain single-chain fragment variable region antibodies, i.e. scFv, dibodies, or other antibody fragments.
Methods of producing such functional equivalents are disclosed in PCT
Application WO
93/21319, European Patent Application No. EP 239400; PCT Application WO
89/09622;
European Patent Application EP 338745; and European Patent Application EP
332424.
Methods of producing such functional equivalents are disclosed in PCT
Application WO
93/21319, European Patent Application No. EP 239400; PCT Application WO
89/09622;
European Patent Application EP 338745; and European Patent Application EP
332424.
[0056] Preferred host cells for transformation of vectors and expression of the receptor antagonists of the present invention are mammalian cells, e.g., COS-7 cells, Chinese hamster ovary (CHO) cells, and cell lines of lymphoid origin such as lymphoma, myeloma (e.g. NSO), or hybridoma cells. Other eukaryotic hosts, such as yeasts, can be alternatively used.
[0057] Where it is desired to express a gene construct in yeast, a suitable selection gene for use in yeast is the trp1 gene present in the yeast plasmid YRp7.
Stinchcomb et al.
Nature, 282: 39 (1979); Kingsman et al., Gene, 7: 141 (1979). The trpl gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1. Jones, Genetics, 85: 12 (1977). The presence of the trpl lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan. Similarly, Leu2-deficient yeast strains (ATCC 20,622 or 38,626) are complemented by known plasmids bearing the Leu2 gene.
Stinchcomb et al.
Nature, 282: 39 (1979); Kingsman et al., Gene, 7: 141 (1979). The trpl gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1. Jones, Genetics, 85: 12 (1977). The presence of the trpl lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan. Similarly, Leu2-deficient yeast strains (ATCC 20,622 or 38,626) are complemented by known plasmids bearing the Leu2 gene.
[0058] The transformed host cells are cultured by methods known in the art in a liquid medium containing assimilable sources of carbon (carbohydrates such as glucose or lactose), nitrogen (amino acids, peptides, proteins or their degradation products such as peptones, ammonium salts or the like), and inorganic salts (sulfates, phosphates and/or carbonates of sodium, potassium, magnesium and calcium). The medium furthermore contains, for example, growth-promoting substances, such as trace elements, for example iron, zinc, manganese and the like.
[0059] As described in the examples below, high affinity anti-EGFR antibodies according to the present invention can be isolated from a phage display library constructed from human heavy chain and light chain variable region genes. For example, a variable domain of the invention can be obtained from a peripheral blood lymphocyte that contains a rearranged variable region gene. Alternatively, variable domain portions, such as CDR
and FW regions, can be obtained from different human sequences. Over 90% of recovered clones after three rounds of selection are specific to EGFR. The binding affinities for EGFR of the screened Fabs are in the nIVI range, which are as high as those of several bivalent anti-EGFR monoclonal antibodies produced using hybridoma technology.
and FW regions, can be obtained from different human sequences. Over 90% of recovered clones after three rounds of selection are specific to EGFR. The binding affinities for EGFR of the screened Fabs are in the nIVI range, which are as high as those of several bivalent anti-EGFR monoclonal antibodies produced using hybridoma technology.
[0060] Antibodies and antibody fragments of the present invention can be obtained, for example, from naturally occurring antibodies, or Fab or scFv phage display libraries. It is understood that, to make a single domain antibody from an antibody comprising a VH and a VL domain, certain amino acid substitutions outside the CDRs can be desired to enhance binding, expression or solubility. For example, it can be desirable to modify amino acid residues that would otherwise be buried in the VH-VL
interface.
interface.
[0061] Further, antibodies and antibody fragments of the invention can be obtained by standard hybridoma technology (Harlow & Lane, ed., Antibodies: A Laboratory Manual, Cold Spring Harbor, 211-213(1998) using transgenic mice (e.g., KM mice from Medium, San Jose, Calif.) that produce human inummoglobulin gamma heavy and kappa light chains. In a preferred embodiment, a substantial portion of the human antibody producing genome is inserted into the genome of the mouse, and is rendered deficient in the production of endogenous =rine antibodies.
Such mice may be immunized subcutaneously (s.c.) with KDR (VEGFR-2) in complete Frames adjuvant.
Such mice may be immunized subcutaneously (s.c.) with KDR (VEGFR-2) in complete Frames adjuvant.
[0062] The protein used to identify EGER binding antibodies of the invention is preferably EGFR and, more preferably, Is the extracefiular domain of EGFR. The BM
extracellular domain can be free or conjugated to another molecule.
extracellular domain can be free or conjugated to another molecule.
[0063] The present invention also provides isolated polynucleotides encoding the antibodies, or fragments thereof, described previously. The invention includes nucleic acids having a sequence encoding one, two, three, four, five and/or all six C)Rs. Table 2 sets forth the nucleic acid sequences.
TABLE
Linea&
CORI aitutgatt actactuag t SEQ ID NO: 1 C052 tacatctatt acageguag caccPctac matt= UMW SEQ ID NO: 3 CDR3 ISiSclign uneaten WIMP Mc SEQ ID NO:
Winne CDR1 RERIP:Rittc stglattft cactadla gcc SEQ ID NO: 9 CDR2 gaticatcca acaguccac t SEQ ID NO: 11 C.DR3 caccastats gtagcacacc tctcact SEQ ID NO: 13
TABLE
Linea&
CORI aitutgatt actactuag t SEQ ID NO: 1 C052 tacatctatt acageguag caccPctac matt= UMW SEQ ID NO: 3 CDR3 ISiSclign uneaten WIMP Mc SEQ ID NO:
Winne CDR1 RERIP:Rittc stglattft cactadla gcc SEQ ID NO: 9 CDR2 gaticatcca acaguccac t SEQ ID NO: 11 C.DR3 caccastats gtagcacacc tctcact SEQ ID NO: 13
[0064) DNA encoding htunan antibodies can be prepared by recombining DNA
encoding human constant regions and variable regions, other than the CDRs, derived substantially or exclusively from the corresponding human antibody regions and DNA
encoding CDRs derived from a human (SEQ ID NOS:1, 3, and 5 for the heavy chain variable domain CDRi and SEQ ID NOS:9, 11, and 13 for the light chain variable domain CDRs).
encoding human constant regions and variable regions, other than the CDRs, derived substantially or exclusively from the corresponding human antibody regions and DNA
encoding CDRs derived from a human (SEQ ID NOS:1, 3, and 5 for the heavy chain variable domain CDRi and SEQ ID NOS:9, 11, and 13 for the light chain variable domain CDRs).
[0065] Suitable sources of DNAs that encode fragments of antibodies include any cell, such as hybridomas and spleen cells, that express the full-length antibody. The fragments may be used by themselves as antibody equivalents, or may be recombined into equivalents, as described above. The DNA deletions and recombinations described in this section may be carried out by known methods, such as those described in the publications listed above with regard to equivalents of antibodies and/or other standard recombinant DNA techniques, such as those described below. Another source of DNAs are single chain antibodies produced from a phage display library, as is known in the art.
[0066] Additionally, the present invention provides expression vectors containing the polynucleotide sequences previously described operably linked to an expression sequence, a promoter and an enhancer sequence. A variety of expression vectors for the efficient synthesis of antibody polypeptide in prokaryotic, such as bacteria and eukaryotic systems, including but not limited to yeast and mammalian cell culture systems have been developed. The vectors of the present invention can comprise segments of chromosomal, non-chromosomal and synthetic DNA sequences.
[0067] Any suitable expression vector can be used. For example, prokaryotic cloning vectors include plasmids from E. coil, such as colE1, pCR1, pBR322, pMB9, pUC, pKSM, and RP4. Prokaryotic vectors also include derivatives of phage DNA such as M13 and other filamentous single-stranded DNA phages. An example of a vector useful in yeast is the 2 , plasmid. Suitable vectors for expression in mammalian cells include well-known derivatives of SV40, adenovirus, retrovirus-derived DNA sequences and shuttle vectors derived from combination of functional mammalian vectors, such as those described above, and functional plasmids and phage DNA.
[0068] Additional eukaryotic expression vectors are known in the art (e.g., P.J.
Southern and P. Berg, J. Mol. Appl. Genet., 1, 327-341 (1982); Subramani et al., Mol.
Cell. Biol., 1: 854-864 (1981); Kaufhiann and Sharp, "Amplification And Expression of Sequences Cotransfected with a Modular Dihydrofolate Reductase Complementary DNA
Gene," J. Mol. Biol. 159, 601-621 (1982); Kaufmann and Sharp, Mol. Cell. Biol.
159, 601-664 (1982); Scahill et al., "Expression And Characterization Of The Product Of A
Human Immune Interferon DNA Gene In Chinese Hamster Ovary Cells," Proc. Nat'l Acad. Sci. USA 80, 4654-4659 (1983); Urlaub and Chasin, Proc. Nat'l Acad. Sci.
USA 77, 4216-4220, (1980).
Southern and P. Berg, J. Mol. Appl. Genet., 1, 327-341 (1982); Subramani et al., Mol.
Cell. Biol., 1: 854-864 (1981); Kaufhiann and Sharp, "Amplification And Expression of Sequences Cotransfected with a Modular Dihydrofolate Reductase Complementary DNA
Gene," J. Mol. Biol. 159, 601-621 (1982); Kaufmann and Sharp, Mol. Cell. Biol.
159, 601-664 (1982); Scahill et al., "Expression And Characterization Of The Product Of A
Human Immune Interferon DNA Gene In Chinese Hamster Ovary Cells," Proc. Nat'l Acad. Sci. USA 80, 4654-4659 (1983); Urlaub and Chasin, Proc. Nat'l Acad. Sci.
USA 77, 4216-4220, (1980).
[0069] The expression vectors useful in the present invention contain at least one expression control sequence that is operatively linked to the DNA sequence or fragment to be expressed. The control sequence is inserted in the vector in order to control and to regulate the expression of the cloned DNA sequence. Examples of useful expression control sequences are the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage lambda, the control region of fd coat protein, the glycolytic promoters of yeast, e.g., the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, e.g., Pho5, the promoters of the yeast alpha-mating factors, and promoters derived from polyoma, adenovirus, retrovirus, and simian virus, e.g., the early and late promoters or SV40, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells and their viruses or combinations thereof.
[0070] The present invention also provides recombinant host cells containing the expression vectors previously described. Antibodies of the present invention can be expressed in cell lines other than in hybridomas. Nucleic acids, which comprise a sequence encoding a polypeptide according to the invention, can be used for transformation of a suitable mammalian host cell.
[0071] Cell lines of particular preference are selected based on high level of expression, constitutive expression of protein of interest and minimal contamination from host proteins. Mammalian cell lines available as hosts for expression are well known in the art and include many immortalized cell lines, such as but not limited to, Chinese Hamster Ovary (CHO) cells, Baby Hamster Kidney (BHK) cells and many others.
Suitable additional eukaryotic cells include yeast and other fungi. Useful prokaryotic hosts include, for example, E. coli, such as E. coli SG-936, E. coli HB 101, E. coli W3110, E. coli X1776, E. coli X2282, E. coli DHI, and E. coliMRC1, Pseudomonas, Bacillus, such as Bacillus subtilis, and Streptomyces.
Suitable additional eukaryotic cells include yeast and other fungi. Useful prokaryotic hosts include, for example, E. coli, such as E. coli SG-936, E. coli HB 101, E. coli W3110, E. coli X1776, E. coli X2282, E. coli DHI, and E. coliMRC1, Pseudomonas, Bacillus, such as Bacillus subtilis, and Streptomyces.
[0072] These present recombinant host cells can be used to produce an antibody, or fragment thereof, by culturing the cells under conditions permitting expression of the antibody or fragment thereof and purifying the antibody or fragment thereof from the host cell or medium surrounding the host cell. Targeting of the expressed antibody or fragment for secretion in the recombinant host cells can be facilitated by inserting a signal or secretory leader peptide-encoding sequence (see, Shokri et al., Appl Microbiol Biotechnol.
60(6):654-64 (2003), Nielsen et al., Prot. Eng. 10:1-6 (1997) and von Heinje et al., Nucl.
Acids Res. 14:4683-4690 (1986)) at the 5 end of the antibody-encoding gene of interest.
These secretory leader peptide elements can be derived from either prokaryotic or eukaryotic sequences. Accordingly suitably, secretory leader peptides are used, being amino acids joined to the N-terminal end of a polypeptide to direct movement of the polypeptide out of the host cell cytosol and secretion into the medium.
60(6):654-64 (2003), Nielsen et al., Prot. Eng. 10:1-6 (1997) and von Heinje et al., Nucl.
Acids Res. 14:4683-4690 (1986)) at the 5 end of the antibody-encoding gene of interest.
These secretory leader peptide elements can be derived from either prokaryotic or eukaryotic sequences. Accordingly suitably, secretory leader peptides are used, being amino acids joined to the N-terminal end of a polypeptide to direct movement of the polypeptide out of the host cell cytosol and secretion into the medium.
[0073] The antibodies of this invention can be fused to additional amino acid residues. Such amino acid residues can be a peptide tag, perhaps to facilitate isolation.
Other amino acid residues for homing of the antibodies to specific organs or tissues are also contemplated.
Other amino acid residues for homing of the antibodies to specific organs or tissues are also contemplated.
[0074] In another embodiment, an antibody of the present invention is made by expressing a nucleic acid encoding the antibody in a transgenic animal, such that the antibody is expressed and can be recovered. For example, the antibody can be expressed in a tissue specific manner that facilitates recovery and purification. In one such embodiment, an antibody of the invention is expressed in the mammary gland for secretion during lactation. Transgenic animals, include but are not limited to mice, goat, and rabbit.
[0075] A method of treating tumor growth in a mammal by administering to the mammal an effective amount of an antibody as previously described is also provided by the present invention. Suitable tumors to be treated according to the present invention preferably express EGFR. While not intended to be bound to any particular mechanism, the diseases and conditions which can be treated or prevented by the present methods include, for example, those in which tumor growth or pathogenic angiogenesis is stimulated through a EGFR paracrine and/or autocrine loop. That is, EGFR
expressing tumors are characteristically sensitive to EGF present in their environment, and can further produce and be stimulated by EGF and/or TGF-a in an autocrine stimulatory loop.
Treatment of such tumors according to the invention includes partial or complete inhibition of tumor growth. Notably, in certain embodiments, inhibition further includes tumor regression.
expressing tumors are characteristically sensitive to EGF present in their environment, and can further produce and be stimulated by EGF and/or TGF-a in an autocrine stimulatory loop.
Treatment of such tumors according to the invention includes partial or complete inhibition of tumor growth. Notably, in certain embodiments, inhibition further includes tumor regression.
[0076] EGFR expression has been observed in a variety of human tumors, both in vitro and in vivo, and the levels of EGFR expression vary widely with tumor type. EGFR
is expressed at varying levels on the cell surface in a significant percentage of human tumors, such as colorectal, head and neck (squamous cell), pancreatic, lung, breast, and renal cell carcinomas, as well as glioblastoma. In certain tumor types, EGFR
expression is very common (e.g., 35% to 70% of ovarian cancers and approximately 25% to 77%
of colorectal cancers). High levels of EGFR expression can occur in correlation with production of receptor ligands (i.e., EGF and TGF-a). EGFR expression has also been correlated with increased resistance to certain chemotherapeutic agents and radiotherapy.
EGFR expression may also serve as a prognostic factor in certain types of tumors, as it has be associated with reduced survival, poor prognosis, and/or increased risk of metastasis.
Moreover, increased EGFR expression exists in multiple tumor types.
is expressed at varying levels on the cell surface in a significant percentage of human tumors, such as colorectal, head and neck (squamous cell), pancreatic, lung, breast, and renal cell carcinomas, as well as glioblastoma. In certain tumor types, EGFR
expression is very common (e.g., 35% to 70% of ovarian cancers and approximately 25% to 77%
of colorectal cancers). High levels of EGFR expression can occur in correlation with production of receptor ligands (i.e., EGF and TGF-a). EGFR expression has also been correlated with increased resistance to certain chemotherapeutic agents and radiotherapy.
EGFR expression may also serve as a prognostic factor in certain types of tumors, as it has be associated with reduced survival, poor prognosis, and/or increased risk of metastasis.
Moreover, increased EGFR expression exists in multiple tumor types.
[0077] Tumors to be treated include primary tumors and metastatic tumors, as well as refractory tumors. Refractory tumors include tumors that fail to respond or are resistant to treatment with chemotherapeutic agents alone, antibodies alone, radiation alone or combinations thereof. Refractory tumors also encompass tumors that appear to be inhibited by treatment with such agents, but recur up to five years, sometimes up to ten years or longer after treatment is discontinued.
[0078] Tumors that can be treated with antibodies of the present invention include tumors that are not vascularized, or not yet substantially vascularized, as well as vascularized tumors. Examples of solid tumors, which can be accordingly treated, include breast carcinoma, lung carcinoma, colorectal carcinoma, pancreatic carcinoma, glioma and lymphoma. Some examples of such tumors include epidermoid tumors, squamous tumors, such as head and neck tumors, colorectal tumors, prostate tumors, breast tumors, lung tumors, including small cell and non-small cell lung tumors, pancreatic tumors, thyroid tumors, ovarian tumors, and liver tumors. Other examples include Kaposi's sarcoma, CNS neoplasms, neuroblastomas, capillary hemangioblastomas, meningiornas and cerebral metastases, melanoma, gastrointestinal and renal carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma, preferably glioblastoma multiforme, and leiomyosarcoma.
[0079] In another aspect of the invention, the anti-EGFR antibodies inhibit tumor-associated angiogenesis. EGFR stimulation of vascular endothelium is associated with vascularization of tumors. Typically, vascular endothelium is stimulated in a paracrine fashion by, e.g., EGF and/or TGF-a from other sources (e.g., tumor cells).
[0080] Accordingly, the human anti-EGFR antibodies are effective for treating subjects with vascularized tumors or neoplasms or angiogenic diseases. Such tumors and neoplasms include, for example, malignant tumors and neoplasms, such as blastomas, carcinomas or sarcomas, and highly vascular tumors and neoplasms. Cancers that can be treated by the methods of the present invention include, for example, cancers of the brain, genitourinary tract, lymphatic system, stomach, renal, colon, larynx and lung and bone.
Non-limiting examples further include epidermoid tumors, squamous tumors, such as head and neck tumors, colorectal tumors, prostate tumors, breast tumors, lung tumors, including lung adenocarcinoma and small cell and non-small cell lung tumors, pancreatic tumors, thyroid tumors, ovarian tumors, and liver tumors. The method is also used for treatment of vascularized skin cancers, including squamous cell carcinoma, basal cell carcinoma, and skin cancers that can be treated by suppressing the growth of malignant keratinocytes, such as human malignant keratinocytes. Other cancers that can be treated include Kaposi's sarcoma, CNS neoplasms (neuroblastomas, capillary hemangioblastomas, meningiomas and cerebral metastases), melanoma, gastrointestinal and renal carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma, including glioblastoma multiforme, and leiomyosarcoma.
Non-limiting examples further include epidermoid tumors, squamous tumors, such as head and neck tumors, colorectal tumors, prostate tumors, breast tumors, lung tumors, including lung adenocarcinoma and small cell and non-small cell lung tumors, pancreatic tumors, thyroid tumors, ovarian tumors, and liver tumors. The method is also used for treatment of vascularized skin cancers, including squamous cell carcinoma, basal cell carcinoma, and skin cancers that can be treated by suppressing the growth of malignant keratinocytes, such as human malignant keratinocytes. Other cancers that can be treated include Kaposi's sarcoma, CNS neoplasms (neuroblastomas, capillary hemangioblastomas, meningiomas and cerebral metastases), melanoma, gastrointestinal and renal carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma, including glioblastoma multiforme, and leiomyosarcoma.
[0081] The present invention also provides a method of treating a non-cancer hyperproliferative disease in a mammal comprising administering to the mammal an effective amount of the antibody of the present invention. As disclosed herein, "hyperproliferative disease" is defined as a condition caused by excessive growth of non-cancer cells that express a member of the EGFR family of receptors. The excess cells generated by a hyperproliferative disease express EGFR at normal levels or they may overexpress EGFR.
[0082] The types of hyperproliferative diseases that can be treated in accordance with the invention are any hyperproliferative diseases that are stimulated by a ligand of EGFR or mutants of such ligands. Examples of hyperproliferative disease include psoriasis, actinic keratoses, and seborrheic keratoses, warts, keloid scars, and eczema.
Also included are hyperproliferative diseases caused by virus infections, such as papilloma virus infection. For example, psoriasis comes in many different variations and degrees of severity. Different types of psoriasis display characteristics such as pus-like blisters (pustular psoriasis), severe sloughing of the skin (erythrodermic psoriasis), drop-like dots (guttae psoriasis) and smooth inflamed lesions (inverse psoriasis). The treatment of all types of psoriasis (e. g., psoriasis vulgaris, psoriasis pustulosa, psoriasis erythrodermica, psoriasis arthropathica, parapsoriasis, palmoplantar pustulosis) is contemplated by the invention.
Also included are hyperproliferative diseases caused by virus infections, such as papilloma virus infection. For example, psoriasis comes in many different variations and degrees of severity. Different types of psoriasis display characteristics such as pus-like blisters (pustular psoriasis), severe sloughing of the skin (erythrodermic psoriasis), drop-like dots (guttae psoriasis) and smooth inflamed lesions (inverse psoriasis). The treatment of all types of psoriasis (e. g., psoriasis vulgaris, psoriasis pustulosa, psoriasis erythrodermica, psoriasis arthropathica, parapsoriasis, palmoplantar pustulosis) is contemplated by the invention.
[0083] In the methods of the present invention, a therapeutically effective amount of an antibody of the invention is administered to a mammal in need thereof.
The term administering as used herein means delivering the antibodies of the present invention to a mammal by any method that can achieve the result sought. They can be administered, for example, intravenously or intramuscularly. Although human antibodies of the invention are particularly useful for administration to humans, they can be administered to other mammals as well. The temi mammal as used herein is intended to include, but is not limited to, humans, laboratory animals, domestic pets and farm animals.
Therapeutically effective amount means an amount of antibody of the present invention that, when administered to a mammal, is effective in producing the desired therapeutic effect, such as inhibiting kinase activity or inhibition of tumor growth.
The term administering as used herein means delivering the antibodies of the present invention to a mammal by any method that can achieve the result sought. They can be administered, for example, intravenously or intramuscularly. Although human antibodies of the invention are particularly useful for administration to humans, they can be administered to other mammals as well. The temi mammal as used herein is intended to include, but is not limited to, humans, laboratory animals, domestic pets and farm animals.
Therapeutically effective amount means an amount of antibody of the present invention that, when administered to a mammal, is effective in producing the desired therapeutic effect, such as inhibiting kinase activity or inhibition of tumor growth.
[0084] The identification of such disease is well within the ability and knowledge of one skilled in the art. For example, human individuals who are either suffering from a clinically significant neoplastic or angiogenic disease or who are at risk of developing clinically significant symptoms are suitable for administration of the present EGFR
antibodies. A clinician skilled in the art can readily determine, for example, by the use of clinical tests, physical examination and medical/family history, if an individual is a candidate for such treatment.
antibodies. A clinician skilled in the art can readily determine, for example, by the use of clinical tests, physical examination and medical/family history, if an individual is a candidate for such treatment.
[0085] The present anti-EGFR antibodies can be administered for therapeutic treatments to a patient suffering from a tumor or angiogenesis associated pathologic condition in an amount sufficient to prevent, inhibit, or reduce the progression of the tumor or pathologic condition. Progression includes, e.g., the growth, invasiveness, metastases and/or recurrence of the tumor or pathologic condition. An amount adequate to accomplish this is defined as a therapeutically effective dose. Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's own immune system. Dosing schedules will also vary with the disease state and status of the patient, and will typically range from a single bolus dosage or continuous infusion to multiple administrations per day (e.g., every 4-6 hours), or as indicated by the treating physician and the patient's condition. It should be noted, however, that the present invention is not limited to any particular dose.
[0086] A cocktail of EGFR antagonists, e.g., monoclonal antibodies, provides an especially efficient treatment for inhibiting the growth of tumor cells. The cocktail can include non-antibody EGFR antagonists and can have as few as 2, 3 or 4 receptor antagonists, and as many as 6, 8 or 10.
[0087] In an embodiment of the invention, anti-EGFR antibodies can be administered in combination with one or more anti-neoplastic agents. For examples of combination therapies, see, e.g., U.S. Patent No. 6,217,866 (Schlessinger et al.) (Anti-EGFR antibodies in combination with anti-neoplastic agents); WO 99/60023 (Waksal et al.) (Anti-EGFR antibodies in combination with radiation). Any suitable anti-neoplastic agent can be used, such as a chemotherapeutic agent, radiation or combinations thereof.
The anti-neoplastic agent can be an alkylating agent or an anti-metabolite.
Examples of alkylating agents include, but are not limited to, cisplatin, cyclophosphamide, melphalan, and dacarbazine. Examples of anti-metabolites include, but not limited to, doxorubicin, daunorubicin, paclitaxel, irinotecan (CPT-11), and topotecan. When the anti-neoplastic agent is radiation, the source of the radiation can be either external (external beam radiation therapy ¨ EBRT) or internal (brachytherapy ¨ BT) to the patient being treated.
The dose of anti-neoplastic agent administered depends on numerous factors, including, for example, the type of agent, the type and severity tumor being treated and the route of administration of the agent. It should be emphasized, however, that the present invention is not limited to any particular dose.
The anti-neoplastic agent can be an alkylating agent or an anti-metabolite.
Examples of alkylating agents include, but are not limited to, cisplatin, cyclophosphamide, melphalan, and dacarbazine. Examples of anti-metabolites include, but not limited to, doxorubicin, daunorubicin, paclitaxel, irinotecan (CPT-11), and topotecan. When the anti-neoplastic agent is radiation, the source of the radiation can be either external (external beam radiation therapy ¨ EBRT) or internal (brachytherapy ¨ BT) to the patient being treated.
The dose of anti-neoplastic agent administered depends on numerous factors, including, for example, the type of agent, the type and severity tumor being treated and the route of administration of the agent. It should be emphasized, however, that the present invention is not limited to any particular dose.
[0088] For treatment of hyperproliferative disease, administration of the antibodies of the invention as described above can be combined with administration of any conventional treatment agent. For example, when the hyperproliferative disease is psoriasis, there are a variety of conventional systemic and topical agents available.
Systemic agents for psoriasis include methotrexate, and oral retinoids, such as acitretin, etretinate, and isotretinoin. Other systemic treatments of psoriasis include hydroxyurea, NSAIDS, sulfasalazine, and 6-thioguanine. Antibiotics and antimicrobials can be used to treat or prevent infection that can cause psoriasis to flare and worsen.
Topical agents for psoriasis include anthralin, calcipotriene, coal tar, corticosteroids, retinoids, keratolytics, and tazarotene. Topical steroids are one of the most common therapies prescribed for mild to moderate psoriasis. Topical steroids are applied to the surface of the skin, but some are injected into the psoriasis lesions.
Systemic agents for psoriasis include methotrexate, and oral retinoids, such as acitretin, etretinate, and isotretinoin. Other systemic treatments of psoriasis include hydroxyurea, NSAIDS, sulfasalazine, and 6-thioguanine. Antibiotics and antimicrobials can be used to treat or prevent infection that can cause psoriasis to flare and worsen.
Topical agents for psoriasis include anthralin, calcipotriene, coal tar, corticosteroids, retinoids, keratolytics, and tazarotene. Topical steroids are one of the most common therapies prescribed for mild to moderate psoriasis. Topical steroids are applied to the surface of the skin, but some are injected into the psoriasis lesions.
[0089] Hyperproliferative disease treatments further include administration of anti-EGFR antibodies in combination with phototherapy. Phototherapy includes administration of any wavelength of light that reduces symptoms of the hyperproliferative disease, as well as photoactivation of a chemotherapeutic agent (photochemotherapy). For farther discussion of treatment of hyperproliferative disorders, see WO
02/11677 (Teufel et al.) (Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists).
02/11677 (Teufel et al.) (Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists).
[0090] Anti-EGFR antibodies of the invention can be administered with EGFR
antagonists, and/or antagonists of other RTKs such as antibodies that block RTK ligands or otherwise neutralize the RTKs. Ligands of EGFR include, for example, EGF, TGF-a amphiregulin, heparin-binding EGF (HB-EGF) and betacellulin. EGF and TGF-a are thought to be the main endogenous ligands that result in EGFR-mediated stimulation, although TGF-a has been shown to be more potent in promoting angiogenesis.
Accordingly, EGFR antagonists include antibodies that bind to such ligands and thereby block binding to and activation of EGFR.
antagonists, and/or antagonists of other RTKs such as antibodies that block RTK ligands or otherwise neutralize the RTKs. Ligands of EGFR include, for example, EGF, TGF-a amphiregulin, heparin-binding EGF (HB-EGF) and betacellulin. EGF and TGF-a are thought to be the main endogenous ligands that result in EGFR-mediated stimulation, although TGF-a has been shown to be more potent in promoting angiogenesis.
Accordingly, EGFR antagonists include antibodies that bind to such ligands and thereby block binding to and activation of EGFR.
[0091] An example of another such RTK is VEGFR. In an embodiment of the present invention, an anti-EGFR antibody is used in combination with a VEGFR
antagonist. In one embodiment of the invention, an anti-EGFR antibody is used in combination with a receptor antagonist that binds specifically to VEGFR-2/KDR
receptor (PCT/US92/01300, filed Feb. 20, 1992; Terman et al., Oncogene 6: 1677-1683 (1991)). In another embodiment, an anti-EGFR antibody is used in combination with a receptor antagonist that binds specifically to VEGFR-1/Flt-1 receptor (Shibuya M. et al., Oncogene 5, 519-524 (1990)). Particularly preferred are antigen-binding proteins that bind to the extracellular domain of VEGFR-1 or VEGFR-2 and block binding by ligand (VEGF
or P1GF), and/or neutralize VEGF-induced or P1GF-induced activation. For example, Mab B4C-1121 binds to soluble and cell surface-expressed KDR. Mab IMC-1121 comprises the VH and VL domains obtained from a human Fab phage display library. (See WO
03/075840) In another example, ScFv 6.12 binds to soluble and cell surface-expressed Flt-1. ScFv 6.12 comprises the VH and VL domains of mouse monoclonal antibody MAb 6.12. A hybridoma cell line producing MAb 6.12 has been deposited as ATCC
number PTA-3344.
antagonist. In one embodiment of the invention, an anti-EGFR antibody is used in combination with a receptor antagonist that binds specifically to VEGFR-2/KDR
receptor (PCT/US92/01300, filed Feb. 20, 1992; Terman et al., Oncogene 6: 1677-1683 (1991)). In another embodiment, an anti-EGFR antibody is used in combination with a receptor antagonist that binds specifically to VEGFR-1/Flt-1 receptor (Shibuya M. et al., Oncogene 5, 519-524 (1990)). Particularly preferred are antigen-binding proteins that bind to the extracellular domain of VEGFR-1 or VEGFR-2 and block binding by ligand (VEGF
or P1GF), and/or neutralize VEGF-induced or P1GF-induced activation. For example, Mab B4C-1121 binds to soluble and cell surface-expressed KDR. Mab IMC-1121 comprises the VH and VL domains obtained from a human Fab phage display library. (See WO
03/075840) In another example, ScFv 6.12 binds to soluble and cell surface-expressed Flt-1. ScFv 6.12 comprises the VH and VL domains of mouse monoclonal antibody MAb 6.12. A hybridoma cell line producing MAb 6.12 has been deposited as ATCC
number PTA-3344.
[0092] Another example of such an RTK is insulin-like growth factor receptor (IGFR). In certain tumor cells, inhibition of EGFR function can be compensated by upregulation of other growth factor receptor signaling pathways, and particularly by IGFR
stimulation. Further, inhibition of IGFR signaling results in increased sensitivity of tumor cells to certain therapeutic agents. Stimulation of either EGFR or IGFR
results in phosphorylation of common downstream signal transduction molecules, including Akt and p44/42, although to different extents. Accordingly, in an embodiment of the invention, an IGFR antagonist (e.g., an antibody that binds to IGF or IGFR and neutralizes the receptor) is coadministered with an antibody of the invention, thereby blocking a second input into the common downstream signaling pathway (e.g., inhibiting activation of Akt and/or p44/42). An example of a human antibody specific for IGFR is IMC-Al2 (See WO
2005/016970).
stimulation. Further, inhibition of IGFR signaling results in increased sensitivity of tumor cells to certain therapeutic agents. Stimulation of either EGFR or IGFR
results in phosphorylation of common downstream signal transduction molecules, including Akt and p44/42, although to different extents. Accordingly, in an embodiment of the invention, an IGFR antagonist (e.g., an antibody that binds to IGF or IGFR and neutralizes the receptor) is coadministered with an antibody of the invention, thereby blocking a second input into the common downstream signaling pathway (e.g., inhibiting activation of Akt and/or p44/42). An example of a human antibody specific for IGFR is IMC-Al2 (See WO
2005/016970).
[0093] Other examples of growth factor receptors involved in tumorigenesis are the receptors for platelet-derived growth factor (PDGF), nerve growth factor (NGF), and fibroblast growth factor (FGF).
[0094] The anti-EGFR antibodies can also be administered with intracellular RTK
antagonists that inhibit activity of RTKs or their associated downstream signaling elements that are involved in tumor growth or tumor-associated angiogenesis.
The intracellular RTK antagonists are preferably small molecules. Some examples of small molecules include organic compounds, organometallic compounds, salts of organic compounds and organometallic compounds, and inorganic compounds. Atoms in a small molecule are linked together via covalent and ionic bonds; the former is typical for small organic compounds such as small molecule tyrosine kinase inhibitors and the latter is typical of small inorganic compounds. The arrangement of atoms in a small organic molecule may represent a chain, e.g. a carbon-carbon chain or carbon-heteroatom chain or may represent a ring containing carbon atoms, e.g. benzene or a policyclic system, or a combination of carbon and heteroatoms, i.e., heterocycles such as a pyrimidine or quinazoline. Although small molecules can have any moleculer weight they generally include molecules that would otherwise be considered biological molecules, except their molecular weight is not greater than 650 D. Small molecules include both compounds found in nature, such as hormones, neurotransmitters, nucleotides, amino acids, sugars, lipids, and their derivatives as well as compounds made synthetically, either by traditional organic synthesis, bio-mediated synthesis, or a combination thereof. See e.g.
Ganesan, Drug Doscov. Today 7(1): 47-55 (Jan. 2002); Lou, Drug Discov. Today, 6(24):
(Dec. 2001).
antagonists that inhibit activity of RTKs or their associated downstream signaling elements that are involved in tumor growth or tumor-associated angiogenesis.
The intracellular RTK antagonists are preferably small molecules. Some examples of small molecules include organic compounds, organometallic compounds, salts of organic compounds and organometallic compounds, and inorganic compounds. Atoms in a small molecule are linked together via covalent and ionic bonds; the former is typical for small organic compounds such as small molecule tyrosine kinase inhibitors and the latter is typical of small inorganic compounds. The arrangement of atoms in a small organic molecule may represent a chain, e.g. a carbon-carbon chain or carbon-heteroatom chain or may represent a ring containing carbon atoms, e.g. benzene or a policyclic system, or a combination of carbon and heteroatoms, i.e., heterocycles such as a pyrimidine or quinazoline. Although small molecules can have any moleculer weight they generally include molecules that would otherwise be considered biological molecules, except their molecular weight is not greater than 650 D. Small molecules include both compounds found in nature, such as hormones, neurotransmitters, nucleotides, amino acids, sugars, lipids, and their derivatives as well as compounds made synthetically, either by traditional organic synthesis, bio-mediated synthesis, or a combination thereof. See e.g.
Ganesan, Drug Doscov. Today 7(1): 47-55 (Jan. 2002); Lou, Drug Discov. Today, 6(24):
(Dec. 2001).
[0095] More preferably, the small molecule to be used as an intracellular RTK
antagonist according to the present invention is an intracellular EGFR
antagonist that competes with ATP for binding to EGFR's intracellular binding region having a kinase domain or to proteins involved in the signal transduction pathways of EGFR
activation.
Examples of such signal transduction pathways include the ras-mitogen activated protein kinase (MAPK) pathway, the phosphatidylinosital-3 kinase (P13K)-Akt pathway, the stress-activated protein kinase (SAPK) pathway, and the signal transducers and activators of transcription (STAT) pathways. Non-limiting examples of proteins involved in such pathways (and to which a small molecule EGFR antagonist according to the present invention can bind) include GR13-2, SOS, Ras, R4 MEK, MAP, and matrix metalloproteinases (MMPs).
antagonist according to the present invention is an intracellular EGFR
antagonist that competes with ATP for binding to EGFR's intracellular binding region having a kinase domain or to proteins involved in the signal transduction pathways of EGFR
activation.
Examples of such signal transduction pathways include the ras-mitogen activated protein kinase (MAPK) pathway, the phosphatidylinosital-3 kinase (P13K)-Akt pathway, the stress-activated protein kinase (SAPK) pathway, and the signal transducers and activators of transcription (STAT) pathways. Non-limiting examples of proteins involved in such pathways (and to which a small molecule EGFR antagonist according to the present invention can bind) include GR13-2, SOS, Ras, R4 MEK, MAP, and matrix metalloproteinases (MMPs).
[0096] One example of a small molecule EGFR antagonist is IRESSA
(ZD1939), which is a quinozaline derivative that functions as an ATP-mimetic to inhibit EGFR. See U.S. Patent No. 5,616,582 (Zeno= Limited); WO 96/33980 (Zeneca Limited) at p.4; see also, Rowinsky etal., Abstract 5 presented at the 37th Annual Meeting of ASCO, San Francisco, CA, 12-15 May 2001; Anido at al., Abstract 1712 presented at the 37th Annual Meeting of ASCO, San Francisco, CA, 12-15 May 2001. Another examples of a small molecule EGFR antagonist is TARCEVA (051-774), which is a 4-(substitutedphenylamino)qubiozaline derivative [6,7-Bis(2-methoxy-ethoxy)-quinazolin4.
y1]- (3-eth3myl-phenyl)amine hydrochloride] EGFR inhibitor. See WO 96/30347 (Pfizer Inc.) at, for example, page 2, line 12 through page 4, line 34 and page 19, lines 14-17. See also Moyer at al., Cancer Res., 57: 4838-48 (1997); Pollack at ad. Phannacol., 291:
739-48(1999). TARCEVA may function by inhibiting phosphorilation of EGFR and its downstream P13/Akt and MAP (mitogen activated protein) kinetic signal transduction pathways resulting in p27-mediated cell-cycle arrest. See Hidalgo at aL, Abstract 281 presented at the 37th Annual Meeting of ASCO, San Francisco, CA, 12-15 May 2001.
(ZD1939), which is a quinozaline derivative that functions as an ATP-mimetic to inhibit EGFR. See U.S. Patent No. 5,616,582 (Zeno= Limited); WO 96/33980 (Zeneca Limited) at p.4; see also, Rowinsky etal., Abstract 5 presented at the 37th Annual Meeting of ASCO, San Francisco, CA, 12-15 May 2001; Anido at al., Abstract 1712 presented at the 37th Annual Meeting of ASCO, San Francisco, CA, 12-15 May 2001. Another examples of a small molecule EGFR antagonist is TARCEVA (051-774), which is a 4-(substitutedphenylamino)qubiozaline derivative [6,7-Bis(2-methoxy-ethoxy)-quinazolin4.
y1]- (3-eth3myl-phenyl)amine hydrochloride] EGFR inhibitor. See WO 96/30347 (Pfizer Inc.) at, for example, page 2, line 12 through page 4, line 34 and page 19, lines 14-17. See also Moyer at al., Cancer Res., 57: 4838-48 (1997); Pollack at ad. Phannacol., 291:
739-48(1999). TARCEVA may function by inhibiting phosphorilation of EGFR and its downstream P13/Akt and MAP (mitogen activated protein) kinetic signal transduction pathways resulting in p27-mediated cell-cycle arrest. See Hidalgo at aL, Abstract 281 presented at the 37th Annual Meeting of ASCO, San Francisco, CA, 12-15 May 2001.
[0097] Other small molecules are also reported to inhibit EGER, many of which are thought to being to the tyrosine kinase domain of an EGFR. Some examples of such small molecule EGFR antagonists are described in WO 91/116051, WO 96/30347, WO
96/33980, WO 97/27199 (Zeneca Limited). WO 97/30034 (Zeneca Limited), WO
97/42187 (Zeneca Limited), WO 97/49688 (Pfizer Inc.), WO 98/33798 (Warner Lambert Company), WO 00/18761 (American Cyanamid Company), and WO 00/31048 (Warner Lambert Company). Examples of specific small molecule EGFR antagonists include Cl-1033 (Pfizer), which is a quinozalme (N-(4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazokin-6-yl]-acrylamide) inhibitor of tyrosine buses, particularly EGFR and is described in WO 00/31048 at page 8, lines 22-6;
P1(I166 (Novartis), which is a pyrrolopyrimidine inhibitor of EGrFR and is described in WO
97/27199 at pages 10-12; GW2016 (GlexoSmidiKline), which is an inhibitor of EGFR and HER2; EKB569 (Wyeth), which is reported to inhibit the growth of tumor calls that overexpress EGFR or HER2 in vitro and in vivo; AG-1478 (Tryphostin), which is a quinazoline small molecule that inhibits signaling from both EGFR and erbB-2;
(Sugen), which is bisubstrate inhibitor that also inhibits protein kinase CK2;
(Parke-Davis) which is reported to inhibit EGFR kinase activity and tumor growth, induce apoptosis in cells in culture, and enhance the cytotoxicity of cytotoxic chemotherapeutic agents; SPM-924 (Schwarz Pharma), which is a tyrosine kinase inhibitor targeted for treatment of prostrate cancer; CP-546,989 (OSI Pharmaceuticals), which is reportedly an inhibitor of angiogenesis for treatment of solid tumors; ADL-681, which is a EGFR kinase inhibitor targeted for treatment of cancer; PD 158780, which is a pyridopyrimidine that is reported to inhibit the tumor growth rate of A4431 xenografts in mice; CP-358,774, which is a quinzoline that is reported to inhibit autophosphorylation in I-1N5 xenografts in mice;
ZD1839, which is a quinzoline that is reported to have antitumor activity in mouse xenograft models including vulvar, NSCLC, prostrate, ovarian, and colorectal cancers;
CGP 59326A, which is a pyrrolopyrimidine that is reported to inhibit growth of EGFR-positive xenografts in mice; PD 165557 (Pfizer); CGP54211 and CGP53353 (Novartis), which are dianilnophthalimides. Naturally derived EGFR tyrosine kinase inhibitors include genistein, herbimycin A, quercetin, and erbstatin.
96/33980, WO 97/27199 (Zeneca Limited). WO 97/30034 (Zeneca Limited), WO
97/42187 (Zeneca Limited), WO 97/49688 (Pfizer Inc.), WO 98/33798 (Warner Lambert Company), WO 00/18761 (American Cyanamid Company), and WO 00/31048 (Warner Lambert Company). Examples of specific small molecule EGFR antagonists include Cl-1033 (Pfizer), which is a quinozalme (N-(4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazokin-6-yl]-acrylamide) inhibitor of tyrosine buses, particularly EGFR and is described in WO 00/31048 at page 8, lines 22-6;
P1(I166 (Novartis), which is a pyrrolopyrimidine inhibitor of EGrFR and is described in WO
97/27199 at pages 10-12; GW2016 (GlexoSmidiKline), which is an inhibitor of EGFR and HER2; EKB569 (Wyeth), which is reported to inhibit the growth of tumor calls that overexpress EGFR or HER2 in vitro and in vivo; AG-1478 (Tryphostin), which is a quinazoline small molecule that inhibits signaling from both EGFR and erbB-2;
(Sugen), which is bisubstrate inhibitor that also inhibits protein kinase CK2;
(Parke-Davis) which is reported to inhibit EGFR kinase activity and tumor growth, induce apoptosis in cells in culture, and enhance the cytotoxicity of cytotoxic chemotherapeutic agents; SPM-924 (Schwarz Pharma), which is a tyrosine kinase inhibitor targeted for treatment of prostrate cancer; CP-546,989 (OSI Pharmaceuticals), which is reportedly an inhibitor of angiogenesis for treatment of solid tumors; ADL-681, which is a EGFR kinase inhibitor targeted for treatment of cancer; PD 158780, which is a pyridopyrimidine that is reported to inhibit the tumor growth rate of A4431 xenografts in mice; CP-358,774, which is a quinzoline that is reported to inhibit autophosphorylation in I-1N5 xenografts in mice;
ZD1839, which is a quinzoline that is reported to have antitumor activity in mouse xenograft models including vulvar, NSCLC, prostrate, ovarian, and colorectal cancers;
CGP 59326A, which is a pyrrolopyrimidine that is reported to inhibit growth of EGFR-positive xenografts in mice; PD 165557 (Pfizer); CGP54211 and CGP53353 (Novartis), which are dianilnophthalimides. Naturally derived EGFR tyrosine kinase inhibitors include genistein, herbimycin A, quercetin, and erbstatin.
[0098] Further small molecules reported to inhibit EGFR and that are therefore within the scope of the present invention are tricyclic compounds such as the compounds described in U.S. Patent No. 5,679,683; quinazoline derivatives such as the derivatives described in U.S. Patent No. 5,616,582; and indole compounds such as the compounds described in U.S. Patent No. 5,196,446.
[0099] In another embodiment, the EGFR antagonist can be administered in combination with one or more suitable adjuvants, such as, for example, cytokines (IL-10 and IL-13, for example) or other immune stimulators, such as, but not limited to, chemokine, tumor-associated antigens, and peptides. See, e.g., Larrivee et al., supra. It should be appreciated, however, that administration of only an anti-EGFR
antibody is sufficient to prevent, inhibit, or reduce the progression of the tumor in a therapeutically effective manner.
antibody is sufficient to prevent, inhibit, or reduce the progression of the tumor in a therapeutically effective manner.
[0100] In a combination therapy, the anti-EGFR antibody is administered before, during, or after commencing therapy with another agent, as well as any combination thereof, i.e., before and during, before and after, during and after, or before, during and after commencing the anti-neoplastic agent therapy. For example, the anti-EGFR
antibody can be administered between 1 and 30 days, preferably 3 and 20 days, more preferably between 5 and 12 days before commencing radiation therapy. In a preferred embodiment of the invention, chemotherapy is administered concurrently with or, more preferably, subsequent to antibody therapy.
antibody can be administered between 1 and 30 days, preferably 3 and 20 days, more preferably between 5 and 12 days before commencing radiation therapy. In a preferred embodiment of the invention, chemotherapy is administered concurrently with or, more preferably, subsequent to antibody therapy.
[0101] In the present invention, any suitable method or route can be used to administer anti-EGFR antibodies of the invention, and optionally, to co-administer anti-neoplastic agents and/or antagonists of other receptors. The anti-neoplastic agent regimens utilized according to the invention, include any regimen believed to be optimally suitable for the treatment of the patient's neoplastic condition. Different malignancies can require use of specific anti-tumor antibodies and specific anti-neoplastic agents, which will be determined on a patient to patient basis. Routes of administration include, for example, oral, intravenous, intraperitoneal, subcutaneous, or intramuscular administration.
The dose of antagonist administered depends on numerous factors, including, for example, the type of antagonists, the type and severity tumor being treated and the route of administration of the antagonists. It should be emphasized, however, that the present invention is not limited to any particular method or route of administration.
The dose of antagonist administered depends on numerous factors, including, for example, the type of antagonists, the type and severity tumor being treated and the route of administration of the antagonists. It should be emphasized, however, that the present invention is not limited to any particular method or route of administration.
[0102] It is noted that an anti-EGFR antibody of the invention can be administered as a conjugate, which binds specifically to the receptor and delivers a toxic, lethal payload following ligand-toxin internalization. The antibody-drug/small molecule conjugate can be directly linked to each other or via a linker, peptide or non-peptide.
[0103] In another aspect of the invention, an anti-EGFR antibody of the invention can be chemically or biosynthetically linked to one or more anti-neoplastic or anti-angiogenic agents.
[0104] The invention further contemplates anti-EGFR antibodies to which target or reporter moieties are linked. Target moieties are first members of binding pairs. Anti-neoplastic agents, for example, are conjugated to second members of such pairs and are thereby directed to the site where the anti-EGFR antibody is bound. A common example of such a binding pair is avidin and biotin. In a preferred embodiment, biotin is conjugated to an anti-EGFR antibody, and thereby provides a target for an anti-neoplastic agent or other moiety, which is conjugated to avidin or streptavidin.
Alternatively, biotin or another such moiety is linked to an anti-EGFR antibody of the invention and used as a reporter, for example in a diagnostic system where a detectable signal-producing agent is conjugated to avidin or streptavidin.
Alternatively, biotin or another such moiety is linked to an anti-EGFR antibody of the invention and used as a reporter, for example in a diagnostic system where a detectable signal-producing agent is conjugated to avidin or streptavidin.
[0105] It is understood that the anti-EGFR antibodies of the invention, where used in a mammal for the purpose of prophylaxis or treatment, will be administered in the form of a composition additionally comprising a pharmaceutically acceptable carrier. Suitable pharmaceutically acceptable carriers include, for example, one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. Pharmaceutically acceptable carriers can further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the binding proteins. The compositions of the injection can, as is well known in the art, be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the mammal.
[0106] The present invention also includes kits for inhibiting tumor growth and/or tumor-associated angiogenesis comprising a therapeutically effective amount of a human anti-EGFR antibody. The kits can further contain any suitable antagonist of, for example, another growth factor receptor involved in tumorigenesis or angiogenesis (e.g., VEGFR-1/Flt-1, VEGFR-2, PDGFR, IGFR, NGFR, FGFR, etc, as described above).
Alternatively, or in addition, the kits of the present invention can further comprise an anti-neoplastic agent. Examples of suitable anti-neoplastic agents in the context of the present invention have been described herein. The kits of the present invention can further comprise an adjuvant; examples have also been described above.
Alternatively, or in addition, the kits of the present invention can further comprise an anti-neoplastic agent. Examples of suitable anti-neoplastic agents in the context of the present invention have been described herein. The kits of the present invention can further comprise an adjuvant; examples have also been described above.
[0107] Moreover, included within the scope of the present invention is use of the present antibodies in vivo and in vitro for investigative or diagnostic methods, which are well known in the art. The diagnostic methods include kits, which contain antibodies of the present invention.
[0108] Accordingly, the present receptor antagonists thus can be used in vivo and in vitro for investigative, diagnostic, prophylactic, or treatment methods, which are well known in the art. Of course, it is to be understood and expected that variations in the principles of invention herein disclosed can be made by one skilled in the art and it is intended that such modifications are to be included within the scope of the present invention.
(0109] Increased EGFR activation is sometimes associated with the conditions that are treated according to the present invention. Higher levels of ligand, EGFR
gene amplification, increased transcription of the receptor or mutations that cause unregulated receptor signaling can result in increased EGFR activation. Amplification of the gene encoding EGFR also results in an increased number of ligands binding to the EGFR, which can further stimulate cell proliferation. EGFR. may be overexpressed in the absence of gene amplification, presumably through mutations that increase EGFR
transcription, mRNA translation, or stability of the protein. EGFR mutants have been identified in gliomas, non-small-cell lung carcinomas, ovarian carcinomas and prostate carcinomas that have a constitutively active tyrosine kinase, suggesting a role for high-level F,GFR activity rather than EGFR overexpression in these cancers. See, e.g., Pedersen et al., Ann. Oncol., 12(6):745-60 (2001). (Type III ECIFR mutation¨variously named EGFItvlii, de2-7 EGFR or AEGFR ¨ lacks a portion of the extracellular ligand binding domain encoded by exons 2-7.); see also Wikstrand at al., Cancer Res., 55:3140-3148 (1995).
EXAMPLES
gene amplification, increased transcription of the receptor or mutations that cause unregulated receptor signaling can result in increased EGFR activation. Amplification of the gene encoding EGFR also results in an increased number of ligands binding to the EGFR, which can further stimulate cell proliferation. EGFR. may be overexpressed in the absence of gene amplification, presumably through mutations that increase EGFR
transcription, mRNA translation, or stability of the protein. EGFR mutants have been identified in gliomas, non-small-cell lung carcinomas, ovarian carcinomas and prostate carcinomas that have a constitutively active tyrosine kinase, suggesting a role for high-level F,GFR activity rather than EGFR overexpression in these cancers. See, e.g., Pedersen et al., Ann. Oncol., 12(6):745-60 (2001). (Type III ECIFR mutation¨variously named EGFItvlii, de2-7 EGFR or AEGFR ¨ lacks a portion of the extracellular ligand binding domain encoded by exons 2-7.); see also Wikstrand at al., Cancer Res., 55:3140-3148 (1995).
EXAMPLES
[0110] The following examples further illustrate the invention, but should not be construed to limit the scope of the invention in any way. Detailed descriptions of conventional methods, such as those employed in the construction of vectors and plasznids, the insertion of genes encoding polypeptides into such vectors and plasmids, the introduction of plasmids into host cells, and the expression and determination thereof of genes and gene products can be obtained from numerous publications, including Sambrook, I. et al., Molecular Cloning: A Laboratory Manual, rd ed., Cold Spring Harbor Laboratory Press (1989).
[01 1 1] Example 1 - Isolation of Human Anti-EGFR Antibodies [0112] Briefly, the human antibodies were isolated from a human naïve Fab bacteriophage library, obtained from Dyax, Cambridge, MA, by biopanning against soluble human EGFR isolated from EGFR-positive tumors. The naïve Fab bacteriophage library containing the heavy and light chain variable regions of the antibody producing cells of human (peripheral B lymphocytes) was constructed from naïve unimmunized humans and tumor-free spleen cells from a patient with gastric carcinoma by amplifying in primary PCR reactions using V gene specific forward and backward primers and cloning these individual VH and VL genes into separate vectors (WO 00/70023).
[0113] The Fab library stock was grown to log phase, rescued with M131(07 helper phage and amplified overnight in 2YTAK medium (2YT containing 100 g/ml of ampicillin and 50 g/ml of kanamycin) at 30 C. The phage preparation was precipitated in 4% PEG/0.5M NaC1, resuspended in 3% fat-free milk/PBS to block nonspecific binding.
[0114] Approximately 1 1012 pfu pre-blocked phage were incubated with 106 EGFR-overexpressing A431 cells in 1 ml plain DMEM medium at 4 C for 1 h, after which cells were washed 15 times with PBS. The bound phage were eluted by incubation at RT for 30 min with 1 ml PBS containing EMC-C225 at 0.5 mg/ml. The eluted phage were incubated with 10 ml of mid-log phase TG1 cells at 37 C for 30 min stationary and 30 min shaking. The infected TG1 cells were pelleted and plated onto several large 2YTAG plates and incubated overnight at 30 C. All the colonies grown on the plates were scraped into 3 to 5 ml of 2YTA medium, mixed with glycerol (10% final concentration), aliquoted, and stored at ¨70 C. For the next round selection, 100 I of the phage stock was added to 25 ml of 2YTAG medium and grown to mid-log phase. The culture was rescued with Ml 3K07 helper phage, amplified, precipitated, and used for selection following the procedure described above.
[0115] Individual TG1 clones recovered after each round of selection were randomly picked and grown at 37 C in 96-well plates and rescued with M13K07 helper phage as described above. The phage preparation was blocked with 1/6 volume of 18%
milk/PBS at RT for 1 h and added to Maxi-sorp 96-well microtiter plates (Ntuic) coated with recombinant EGFR (1 jig/mix 100 p.1). After incubation at RT for 1 h, the plates were washed three times with PBST and incubated with a mouse anti-M13 phage-HRP
conjugate (Amersham Pharmacia Biotech, Piscataway, NJ). The plates were washed five times, TMB peroxidase substrate (KPL, Gaithersburg, MD) added, and the absorbance at 450 nm read using a microplate reader (Molecular Devices, Sunnyvale, CA).
[0116] Identified clones were further tested for blocking of EGF binding. DNA
fingerprinting of clones was used to differentiate unique clones.
Representative clones of each digestion pattern were picked and subject to DNA sequencing.
[0117] Example 2 - Expression and purification of the soluble Fab fragments.
[0118] Plasmids containing the genes encoding the 11F8 Fab were used to transform a nonsuppressor E. coli host HB2151. Expression of the Fab fragments in HB2151 was induced by culturing the cells in 2YTA medium containing 1 mM
isopropyl-1-thio-3-D-galactopyranoside (IPTG, Sigma) at 30 C. A periplasmic extract pf the cells was prepared by resuspending the cell pellet in 25 mM Tris (pH 7.5) containing 20% (w/v) sucrose, 200 mM NaC1, 1mM EDTA, and 1 mM PMSF, followed by incubation at 4 C
with gentle shaking for 1 h. After centrifugation, the soluble Fab protein was purified from the supernatant by affinity chromatography using a Protein G column, following the manufacturer's protocol (Amersham Pharmacia Biotech).
[0119] Example 3 - Construction of Human Anti-EGFR IgG1 Antibodies [0120] The human anti-EGFR Fab was engineered into a full human IgGl. A
selected Fab candidate, Cl1F8, was identified from a human naive Fab phage display library for high affinity binding to, and ligand blocking activity of human EFGR (ErbB).
The DNA sequences encoding the variable regions of the 11F8 Fab light (SEQ ID
NO:15) and heavy chain genes were obtained (SEQ ID NO:7) by PCR amplification and cloned into an expression vector containing the human IgGi constant domains using the glutamine s3mthase expression system from Lonza Biologics, Inc.
[0121] PCR
amplification was performed in two steps utilizing the Expand PCR
kit (Boehringer Mannheim, Inc.) according to the manufacturer's specifications and the primers listed in Table 3.
TABLE 3- PCR Amplification Primers Primer Nucleotide Sequence SEQ ID NO:
C11F8HF 5'TCCTTTTTCTAGTAGCAACTGCAACTGGAGTACATTCACAGGTGCAGCTGCAGAA-3' 20 C11F8HR 5'-CGAGCTAGCGCTTGAGACGGTGACCAGGGTG-3' 21 C11F8LF 5'- TCCTTTTTCTAGTAGCAACTGCAACTGGAGTACATTCAGAAATTGTGATGACACA-3' 22 C11F8LR 5'-CGATCTAGAACTCACGTTTGATCTCCGCCTTGGTC-3' 23 OSIF 5'-GAGAAGCTTGCCGCCACCATOGGATGGTCATGTATCATCCTTTTTCTAGTAGC-3' 24 [0122] Briefly, the PCR products of heavy and light chains were amplified utilizing 25 ng Cl1F8 Fab plasmid DNA as template and the pair of forward and reverse primers for the heavy (C11F8HF and Cl1F8HR) and light chains (C11F8LF and Cl1F8LR) in 50 ItL Expand Buffer System #3 reactions under the following cycling conditions in Table 4:
1 cycle 94 C 2 minutes cycles 94 C 20 seconds 48 C 2 minutes 68 C 20 seconds 20 cycles 94 C 20 seconds 65 C 60 seconds 68 C 2 minutes 1 cycle 65 C 5 minutes [0123] The resulting PCR products add a 57-base pair sequence to the 5' end of the immunoglobulin genes encoding a 19-amino acid mouse heavy chain gene signal sequence (MGWSCHLFLVATATGVHS, SEQ ID NO:25), which enables efficient immunoglobulin processing and secretion. For efficient initiation of translation of genes in mammalian cells, a consensus "Kozak" sequence (I Mol. Biol. 196:947) was added by amplifying the heavy and light chain in a secondary PCR reaction using the forward primer, OSIF in combination with CH11F8HR or C I1F8LR respectively. This PCR
product also provides a 5' Hind III restriction endonuclease site for cloning of the amplified product into suitable expression vector, [0124] Agarose gel-purified Hind 111-Nhe I heavy chain fragment was cloned into a CMV promoter-driven vector, pDFc (Figure 1A) to generate a contiguous cDNA
coding region of variable and constant region DNA sequence. A Hind III-Xba I light chain fragment was cloned into a second CM' promoter-driver vector, p12.1L (Figure 1B). The resulting construct contains a single intron separating the variable light and kappa constant regions, which is efficiently spliced from nascent RNA transcript. The recombinant plastnids were transformed into competent E. coil and selected plasmid isolates were screened for transient co-expression of the heavy and light chains in COS
cells.
[0125] Example 4 - Expression of Human Anti-EGFR IgG1 Antibodies [0126] For stable transfection, a single plasmid vector was generated by cloning the Not I-Sal I fragment of the CMV promoter-containing heavy chain expression cassette into the light chain-containing p12.1L vector. The resulting plasmid vector, pGS-I1F8 was restriction mapped (see, Figure IC). The restriction digest analysis was shown in Figure 2.
[0127] The recombinant cell line used for the production of 11F8 monoclonal antibody is derived from the non-secreting murine myeloraa cell line, NSO
(refered to in Barnes et al., Cytotechnology 32:109(2000)). The NSO cell line was obtained from Lonza Biologics, Inc. (Slough, Berkshire, UK).
[0128] The myeloma cell line, NSO was transfected with plasmid, pGS-11F8 via electroporation using the BioRad Gene Pulsar set at a voltage of 250V with a capacitance of 400 uFd and an observed time constant of 9.0 msec. The electroporated cells were resuspended in DMEM (RH Biosciences, Inc., Lenexa, KS) containing 10%
dialyzed fetal calf serum, crFCS (HyClone, Logan, UT) and 2 mM glutamine (inVitrogen/Life Technologies, Paisley, PA). 50 ul of the resuspended cells were seeded into 96-well plates at a density of 5,000-10,000 cells per well. Glutamine synthetase (GS)-positive transfectants were selected by addition of glutamine-free DMEM medium containing 10% dFCS, supplemented with 1 x GS (JRH Biosciences, Inc.) 24-h post-transfection. Cells were cultured for 2-4 weeks at 37 C, 5% CO2 to enable growth and expansion of colonies prior to screening for antibody-expressing clones.
[0129] Clones expressing anti-EGFR antibody were screened using a horseradish peroxidase anti-human Fc (gamma)-based ELISA and detection was carried out at A450nm.
Positive clones were expanded and retested over 3-5 days cultivation period.
Strong positives (antibody production of 25 _tL/mg or more) were expanded for further analysis.
Based on antibody batch production results of 249 [tg/mL, Clone #34 was selected for limiting dilution subcloning and reassessed. Clone 34-5 was selected based on consistent production levels, comparable to or better than the parent cell line (batch production = 310 Itg/mL, fed-batch = 0.75 ¨ 0.8 g/L). Clone #34-5-3 was isolated after a second round of subcloning and analysis showed that Clone #34-5-3 produces a high level of antibody (batch production = 324 g/mL, fed-batch = 1.0 ¨ 1.2 g/L). Further characterization of this clone was carried out in the following examples.
[0130] Example 5 - In Vitro Binding of Antibodies to EGFR.
[0131] Antibodies were screened in a solid state ELISA comparing the binding characteristics of IMC-11F8 and IMC-C225. Ninety six-well microtiter plate was coated overnight with 1 1.1g/mL in carbonate buffer at 4 C. Plates were blocked with phosphate buffered saline (PBS) supplemented with 10% new born calf serum for one hour at 37 C.
Various amounts of IIVIC-11F8 or IMC-C225 were added to the plates and incubated at room temperature for a further 60 minutes, followed by washing with PBS. Mouse anti-human Fc antibody-horse radish peroxidase (HRP) conjugate were added and incubated for an additional 60 minutes at room temperature, followed by extensive washing with PBS. The plate was then incubated with HRP substrate for 30 sec. ¨2 min. and the reaction stopped with 0.1 M H2SO4. The plates were read using an ELISA reader at OD450nrn=
[0132] Figure 3 shows the binding of IMC-11F8 and IMC-C225 antibodies to EGFR. Both IMC-11F8 and IMC-C225 exhibit comparable binding to EGFR.
[0133] Example 6- Binding Kinetics of Anti-EGFR Antibodies [0134] The binding kinetics of IMC-11F8 and IIVIC-C225 IgG antibodies and their respective Fab fragittents were measured using a BlAcore sensor (Pharmacia Biosensor, ) EGFR-AP fusion protein was immobilized onto a sensor chip and soluble IMC-l1F8 and EMC-C225 antibodies were injected at concentrations ranging from 1.5 uhf to 100 uhf.
Sensorgrams were obtained at each concentration and were analyzed with BIA
Evaluation 2.0, a program to determine the rate constants, lcu,, and koff. The affinity constant Kd, was calculated from the ratio of rate constants, Irodlro,, [0135] The binding kinetics of the anti-EGFR antibodies of the present invention are illustrated in Table 5. These show that both IgG antibodies have comparable binding kinetics to EGFR.
Antibody Format Icon (105 M4113 koff (leo lCd (nM) IMC-11F8 Fab 22.9 + 9.9 36.7 + 8.5 1.78 + 0.5:
IMC-11F8 IgG 18.6 + 7.7 5.8 + 2.2 0.32 + 0.06 IMC-C225 Fab 23.1 + 4.8 111 + 3.4 0.53 + 0.17 ]MC-C225 IgG 21.3 + 7.3 5.4 + 1.0 0.3 + 0.2 The results represent the mean + SE from at least three separate determinations.
[0136] Example 7 - Specificity of the Antibodies for EGFR
[0137] Antibody binding to EGFR was evaluated by a 1251-EGF competition assay.
HT29 cells were seeded at 2 x 104 cells per well in 24-well COSTAR plates (Fisher Scientific, U.S.A.) in McCoy's 5a medium supplemented with 1.5 mM L-glutamine, 10%
CS and antibiotics at 37 C. The cell monolayer was then incubated at room temperature for 1 hour with various concentrations of unlabeled EGF, 11F8 or 1MC-C225 that were mixed with various amounts of 12514abe1ed EGF. Cells were washed with cold PBS
and cell-associated radioactivity was measured in a gamma counter.
* Trade-mark [0138] Figure 4 shows the inhibition of 125I-EGF binding to EGFR on H1'29 cells.
At concentrations of between 10 to 100nM, INIC-11F8 is as efficient as IMC-C225 in inhibiting 1251-EGF binding to EGFR on HT29 cells. Both antibodies are better at competing for binding than EGF, the natural ligand of MFR. Similar results were observed for inhibition of 125I-EGF binding to EGFR on A431 cells.
[0139] Example 8- EGFR Activation [0140] Briefly, a lcinase receptor activation assay (KIRA assay), or phosphorylation assay, was carried out using ThcPC3 or A431 cells. Cells were first grown to 90% continency in DME supplemented with 4 triM leglutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose, 10% CS, at 37 C. Prior to experimentation, the cells were starved for 24 bin DME supplemented with 0.5% CS. To evaluate the effects of antibodies, Th4C-11F8,1MC-C225 and EVIC-1C11 on EGF-induced activation of EGFR, various concentrations of antibodies were prebound at room temperature for 30 minutes, followed by stimulation with EGF at 8 ng/mL for another 15 minutes.
Following stimulation, cell monolayers were washed with ice cold PBS containing 1 rnM
sodium orthovanadate. Cells were lysed in lysis buffer [20 mM Tric-HC1, pH. 7.4,1%
Triton X-100,137 mM NaCI, 10% glycerol, 10 mM EDTA, 2 mM sodium orthovanadate, 100 niM
NaF, 100 mM sodium pyrophosphate, 5 inM PEFABLOC SC (Boehringer Mannheim Biochemicals, Indianapolis, IN), 100 lig aprotinin and 100 itg/mL leupeptin]
and centrifuged at 14,000 x g for 10 minutes. Cleared cell lysates were added to wells of 96-well plates coated with polyclonal anti-EGFR antibody. The plates were washed to remove non-specifically bound proteins and the level of Et3FR phosphorylation was assessed by the addition of anti-phosphotyrosine antibody. Upon extensive washing, the amount of bound anti-phoshotyrosine antibody was measure using an BLISA reader at OD4sown-[0141] The results show a marked decrease in phosphorylation of FOR by RAC-1 IFS antibody in both BxPC3 (Figure 5) and A431 (Figure 6) cells tested as compared to control antibody, IMC-1C11.
[0142] Inhibition of FGF-stimulated EGFR phosphoryiation was further evaluated by Western blot analysis of the immunoprecipitatecl EGFR. A431 cells were prebound with antibodies followed by stimulation with EGF as described above. A control antibody that binds to EGFR but does not inhibit EGFR phosphorylation was used. Protein (EGFR) was immunoprecipitated from the cleared lysates using polyclonal anti-EGFR
antibody followed by Protein A Sepharosebeads. The bound-beads were then washed once with 0.2% Triton X-100, 10 mM Tris-HC1, pH 8.0,150 niM NaC1, 2 !TIM BDTA (Buffer A), twice with Buffer A containing 500 DWI NaC1 and twice with Tris-HCI, pH 8Ø
Drained beads were mixed with 30 ML 2 X SDS loading buffer, boiled and the supernatant was subjected to SDS-PAGE. After separation of proteins by electrophoresis, the protein bands were transferred onto nitrocellulose filters for Western Blot analysis.
Filters were blocked overnight in blocking buffer, 50 mM Tris-HC1, p117.4, 150 inM Neel (TBS) containing 5% bovine serum albumin and 10% nonfat dried milk. To detect phosphorylated receptor, blots were probed with an anti-phosphotyrosine antibody in blocking buffer for 1 hour at room temperature. Blots were then washed extensively with 0.5 x TBS containing 0.1% Tween-20 (TBS-T) and incubated with god anti-mouse Ig conjugated to HRP (Amersham, little Chalfont, UK). Blots were washed with TBS
and incubated for 1 minute with a chemilumineseence reagent (ECL, Junersham, Little Chalfont, U.K.). Anti-phosphotyrosine reacting with phosphorylated proteins was detected by exposure to a high performance luminescence detection film (Hyperfilm*-ECL, Amersham, Little Chalfont, U.K.) for 0.5 to 10 minutes.
[0143] Western blot analysis in Figure 7A shows that IMC-I1F8, like IMC-C225, inhibits EGFR phosphorylation. Neither EGF-antibody nor the control antibody-treated cells completely inhibits EGFR phosphorylation. Figure 7B shows that synthesis of EGFR
is not inhibited with the addition of antibodies to the cells. Figure 8 shows that phosphorylation of EGFR is inhibited by 1MC-11F8. Greater than 70% inhibition was observed for three tumor cell lines of different origin (A431, 13xPC3, HT-29) at the lowest antibody concentration tested (0.8 nM).
[0144] The effect of 1MC-11F8 on one of the major downstream signaling molecules of EGFR, MAP kinases p44442, was also examined. 1MC-11F8 blocked p44/42 MAP kinases phosphorylation following EGF stimulation in A431, BxPC3 and HT-29 cells in a dose-dependent manner (Fig. 4).
* Trade-mark [0145] Example 9 - Inhibition of Cell Proliferation [0146] The MTT Cell Proliferation Assay is measured color-metrically as a result of reduction of the yellow tetrazolium, MTT (3-(4, 5-dimethylthiazoly1-2)-2, 5-phenyltetrazolium bromide) by metabolically active cell to an intracellular purple formazan product, which can be solubilized and quantified by spectrophotometric means.
Briefly, DiFi cells were cultured overnight in DMEM-10% CS. Antibodies, IMC-11F8, IMC-C225 or IN4C-1C11 were added to triplicate wells and incubated for an additional 72 hours at 37 C, 5% CO2. To measure cell growth, a 20 1., aliquot of tetrazolium dye was added to each well and the cells were incubated for 3 hours at 37 C. When the purple precipitate was clearly visible under a microscope, the cells were lysed by addition of 100 pi detergent reagent. Absorbance of the formazan product was measured at OD57onm as a quantitation of proliferation.
[0147] As shown in Figure 9, unlike control antibody EVIC-1C11, IMC-11F8 is as potent an inhibitor of cell proliferation as IMC-C225.
[0148] Example 10 - Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity [0149] One method of assessing cell death is via an antibody dependent cell-mediated cytotoxicity assay or ADCC, which generally use the radioisotope 51Cr. Target cells labeled with 51Cr were mixed with antibody and the degree of killing was assessed by release of 51Cr. Briefly, approximately 3 x 106 DiFi cells were suspended in 0.5 ml culture medium and 0.5 mCi of Na51Cr04 was added. The mixture was incubated for 1 h at with occasional shaking. The cells were then washed three times with cold culture medium. The labeled cells were then suspended in 100 p.1 culture medium containing varying concentrations of anti-EGFR antibodies (IMC-11F8 or INIC-C225) and incubated for 30 minutes at 4 C. The cells were then washed three times with culture medium by centrifugation. Rabbit complement was added and the treated cells were further incubated at 37 C for 1 h. 50 pl of cold medium were then added and centrifuged. The supernatants were then removed and the radioactivity released by the cells into the supernatant was measured in a gamma counter. The maximum release of the radioactivity was obtained by adding 1% Triton X to the target cells. The percent cytotoxicity was calculated as cpm experimental release minus cpm background times 100%, which is then divided by the cpm maximum release minus rpm background.
[0150] Figure 10 shows IMC-11178 and 1A4C-C225 (or ERBrr(Jxe mediate cell death via activation of the Antibody Dependent Cellular Cytotoxicity or ADCC
activity).
[0151] Example 11 -In Vivo Inhibition of Tumor Cell Growth in Mice [0152] In vivo anti-tumor studies were designed to determine if1MC-11F8 would block the growth of tumor cells in a xenograft model. Athymic mice (nu/nu;
Charles River Lab, Wilmington. MA) were injected subcutaneously with 1-2 million A431 or Bx.PC-3 cells in the flank. Anti-FsGFR antibodies (Th4C-11F8 and 1MC-C225) or control antibody was administered intraperitoneally at either 1 mg/dose or 0.3 mg/dose, three times per week. Tumor size was measured at least three times per week with a caliper and tumor volume calculated (See, e.g. Baselga at aL, J Natl. Cancer hist (1993) 85:1327-1333) [0153] Figure 11 shows the anti-tumor activity of IMC-11F8 in A431 xenograft model At 1 mg dose (Figure 11, right panel, TMC-11F8 is as effective as IMC-(CETUXEMAB) in suppressing or inhibiting tumor growth as compared to control animals. At a lower dose of 0.3 mg, progression of tumor growth is retarded.
Similarly, Figure 12 shows the effect of1MC-11F8 and 1MC-C225 in a second tumor model (BxPC-3 xenograft). The kinetics of Ifx.PC3 tumor growth is similar to that observed in the A431 tumor model. At the 1.0 mg/mouse/injection dose level IMC-1 IFS led to 6 tumor regressions out of 8 A413-bearing animals, and 5 tumor regression out of 8 13xPC3-bearing mice.
[0154] Immunolistochemistry staining of both A431 and BxPC3 xenograft sections revealed that DvIC-11F8 treatment markedly reduced the tumor cell density and increased the area of necrotic acellular debris within the tumors (Fig. 13).
Further, IMC-11F8 reduced the percentage of Ki-67 positive cells across the entire tumor section, indicating a reduction in cell proliferation within the tumors (F18. 13).
(01551 Example 12¨ IMC.11Fil Combination Therapy [0156] Nude mice bearing human colorectal tumor xenografts, GEO, DLD-1, or HT-29, of approximately 200-300 mm3 were treated by interperitoneal injection of IMC-11F8 twice a week at 0.3 mg or 1.0 mg/injection, alone or in combination with irinotecan (CPT-11) at a dose of 100 mg/kg once a week. Tumor sizes were measured twice a week.
[0157] Treatment with IMC-11F8 at either 0.3 mg or 1.0 mg/mouse/injection significantly inhibited the growth of all three colorectal xenografts (GEO, DLD-1, or HT-29; Fig. 14A-C). When administered to mice bearing GEO xenografts in combination with CPT-11, IMC-11F8 significantly increased the tumor growth inhibition observed with CPT-11 alone (Fig. 14A; p<0.01 for both doses of IMC-11F8). Moreover while CPT-11 alone caused no tumor regressions in this model, 4 out of 10 and 9 out of 10 tumor regressions were achieved when CPT-11 was combined with IMC-11F8 at 0.3 mg or 1.0 mg/mouse/injection, respectively (p = 0.004 and p<0.0001, respectively). Similar combinational anti-tumor effects were observed in two other xenografts, DLD-1 (Fig.
14B) and HT-29 (Fig. 14C) with equivalent statistical significance in tumor regression in the higher antibody dose (1.0 mg) group. Fig. 14D illustrates the significant increase in the number of tumor regressions observed when CPT-11 is combined with IMC-11F8 in these three colorectal carcinoma xenografts models.
[0158] Example 13 ¨ Pharmacokinetics of IMC-11F8 [0159] The pharmacokinetics of lIVIC-11F8 was studied in cynomolgus monkeys and compared to the pharmacokinetics of IMC-C225. A single dose pharmacokinetic study at 20.5 mg/kg 1251-radio-labeled IMC-11F8 and IMC-C225 was separately injected intravenously in monkey and blood was drawn at day to determine the level of antibody that is retained in the plasma of the animal. Table 6 provides a pharmacokinetics comparison of IMC-11F8 and IMC-C225 in cynomolgus monkeys.
Caux (n18/1-) 1213 1161 Timx (hrs) 0.75 0.117 Tin (bra) 116 117 AUC (mg*br/L) 115400 97871 CI (n.L/br) 0.736 0.636 [0160] It will be understood by one skilled in the art that the scope of the claims should not be limited by the preferred embodiment or examples but should be given the broadest interpretation consistent with the description as a whole.
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.
NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
NOTE: For additional volumes please contact the Canadian Patent Office.
[01 1 1] Example 1 - Isolation of Human Anti-EGFR Antibodies [0112] Briefly, the human antibodies were isolated from a human naïve Fab bacteriophage library, obtained from Dyax, Cambridge, MA, by biopanning against soluble human EGFR isolated from EGFR-positive tumors. The naïve Fab bacteriophage library containing the heavy and light chain variable regions of the antibody producing cells of human (peripheral B lymphocytes) was constructed from naïve unimmunized humans and tumor-free spleen cells from a patient with gastric carcinoma by amplifying in primary PCR reactions using V gene specific forward and backward primers and cloning these individual VH and VL genes into separate vectors (WO 00/70023).
[0113] The Fab library stock was grown to log phase, rescued with M131(07 helper phage and amplified overnight in 2YTAK medium (2YT containing 100 g/ml of ampicillin and 50 g/ml of kanamycin) at 30 C. The phage preparation was precipitated in 4% PEG/0.5M NaC1, resuspended in 3% fat-free milk/PBS to block nonspecific binding.
[0114] Approximately 1 1012 pfu pre-blocked phage were incubated with 106 EGFR-overexpressing A431 cells in 1 ml plain DMEM medium at 4 C for 1 h, after which cells were washed 15 times with PBS. The bound phage were eluted by incubation at RT for 30 min with 1 ml PBS containing EMC-C225 at 0.5 mg/ml. The eluted phage were incubated with 10 ml of mid-log phase TG1 cells at 37 C for 30 min stationary and 30 min shaking. The infected TG1 cells were pelleted and plated onto several large 2YTAG plates and incubated overnight at 30 C. All the colonies grown on the plates were scraped into 3 to 5 ml of 2YTA medium, mixed with glycerol (10% final concentration), aliquoted, and stored at ¨70 C. For the next round selection, 100 I of the phage stock was added to 25 ml of 2YTAG medium and grown to mid-log phase. The culture was rescued with Ml 3K07 helper phage, amplified, precipitated, and used for selection following the procedure described above.
[0115] Individual TG1 clones recovered after each round of selection were randomly picked and grown at 37 C in 96-well plates and rescued with M13K07 helper phage as described above. The phage preparation was blocked with 1/6 volume of 18%
milk/PBS at RT for 1 h and added to Maxi-sorp 96-well microtiter plates (Ntuic) coated with recombinant EGFR (1 jig/mix 100 p.1). After incubation at RT for 1 h, the plates were washed three times with PBST and incubated with a mouse anti-M13 phage-HRP
conjugate (Amersham Pharmacia Biotech, Piscataway, NJ). The plates were washed five times, TMB peroxidase substrate (KPL, Gaithersburg, MD) added, and the absorbance at 450 nm read using a microplate reader (Molecular Devices, Sunnyvale, CA).
[0116] Identified clones were further tested for blocking of EGF binding. DNA
fingerprinting of clones was used to differentiate unique clones.
Representative clones of each digestion pattern were picked and subject to DNA sequencing.
[0117] Example 2 - Expression and purification of the soluble Fab fragments.
[0118] Plasmids containing the genes encoding the 11F8 Fab were used to transform a nonsuppressor E. coli host HB2151. Expression of the Fab fragments in HB2151 was induced by culturing the cells in 2YTA medium containing 1 mM
isopropyl-1-thio-3-D-galactopyranoside (IPTG, Sigma) at 30 C. A periplasmic extract pf the cells was prepared by resuspending the cell pellet in 25 mM Tris (pH 7.5) containing 20% (w/v) sucrose, 200 mM NaC1, 1mM EDTA, and 1 mM PMSF, followed by incubation at 4 C
with gentle shaking for 1 h. After centrifugation, the soluble Fab protein was purified from the supernatant by affinity chromatography using a Protein G column, following the manufacturer's protocol (Amersham Pharmacia Biotech).
[0119] Example 3 - Construction of Human Anti-EGFR IgG1 Antibodies [0120] The human anti-EGFR Fab was engineered into a full human IgGl. A
selected Fab candidate, Cl1F8, was identified from a human naive Fab phage display library for high affinity binding to, and ligand blocking activity of human EFGR (ErbB).
The DNA sequences encoding the variable regions of the 11F8 Fab light (SEQ ID
NO:15) and heavy chain genes were obtained (SEQ ID NO:7) by PCR amplification and cloned into an expression vector containing the human IgGi constant domains using the glutamine s3mthase expression system from Lonza Biologics, Inc.
[0121] PCR
amplification was performed in two steps utilizing the Expand PCR
kit (Boehringer Mannheim, Inc.) according to the manufacturer's specifications and the primers listed in Table 3.
TABLE 3- PCR Amplification Primers Primer Nucleotide Sequence SEQ ID NO:
C11F8HF 5'TCCTTTTTCTAGTAGCAACTGCAACTGGAGTACATTCACAGGTGCAGCTGCAGAA-3' 20 C11F8HR 5'-CGAGCTAGCGCTTGAGACGGTGACCAGGGTG-3' 21 C11F8LF 5'- TCCTTTTTCTAGTAGCAACTGCAACTGGAGTACATTCAGAAATTGTGATGACACA-3' 22 C11F8LR 5'-CGATCTAGAACTCACGTTTGATCTCCGCCTTGGTC-3' 23 OSIF 5'-GAGAAGCTTGCCGCCACCATOGGATGGTCATGTATCATCCTTTTTCTAGTAGC-3' 24 [0122] Briefly, the PCR products of heavy and light chains were amplified utilizing 25 ng Cl1F8 Fab plasmid DNA as template and the pair of forward and reverse primers for the heavy (C11F8HF and Cl1F8HR) and light chains (C11F8LF and Cl1F8LR) in 50 ItL Expand Buffer System #3 reactions under the following cycling conditions in Table 4:
1 cycle 94 C 2 minutes cycles 94 C 20 seconds 48 C 2 minutes 68 C 20 seconds 20 cycles 94 C 20 seconds 65 C 60 seconds 68 C 2 minutes 1 cycle 65 C 5 minutes [0123] The resulting PCR products add a 57-base pair sequence to the 5' end of the immunoglobulin genes encoding a 19-amino acid mouse heavy chain gene signal sequence (MGWSCHLFLVATATGVHS, SEQ ID NO:25), which enables efficient immunoglobulin processing and secretion. For efficient initiation of translation of genes in mammalian cells, a consensus "Kozak" sequence (I Mol. Biol. 196:947) was added by amplifying the heavy and light chain in a secondary PCR reaction using the forward primer, OSIF in combination with CH11F8HR or C I1F8LR respectively. This PCR
product also provides a 5' Hind III restriction endonuclease site for cloning of the amplified product into suitable expression vector, [0124] Agarose gel-purified Hind 111-Nhe I heavy chain fragment was cloned into a CMV promoter-driven vector, pDFc (Figure 1A) to generate a contiguous cDNA
coding region of variable and constant region DNA sequence. A Hind III-Xba I light chain fragment was cloned into a second CM' promoter-driver vector, p12.1L (Figure 1B). The resulting construct contains a single intron separating the variable light and kappa constant regions, which is efficiently spliced from nascent RNA transcript. The recombinant plastnids were transformed into competent E. coil and selected plasmid isolates were screened for transient co-expression of the heavy and light chains in COS
cells.
[0125] Example 4 - Expression of Human Anti-EGFR IgG1 Antibodies [0126] For stable transfection, a single plasmid vector was generated by cloning the Not I-Sal I fragment of the CMV promoter-containing heavy chain expression cassette into the light chain-containing p12.1L vector. The resulting plasmid vector, pGS-I1F8 was restriction mapped (see, Figure IC). The restriction digest analysis was shown in Figure 2.
[0127] The recombinant cell line used for the production of 11F8 monoclonal antibody is derived from the non-secreting murine myeloraa cell line, NSO
(refered to in Barnes et al., Cytotechnology 32:109(2000)). The NSO cell line was obtained from Lonza Biologics, Inc. (Slough, Berkshire, UK).
[0128] The myeloma cell line, NSO was transfected with plasmid, pGS-11F8 via electroporation using the BioRad Gene Pulsar set at a voltage of 250V with a capacitance of 400 uFd and an observed time constant of 9.0 msec. The electroporated cells were resuspended in DMEM (RH Biosciences, Inc., Lenexa, KS) containing 10%
dialyzed fetal calf serum, crFCS (HyClone, Logan, UT) and 2 mM glutamine (inVitrogen/Life Technologies, Paisley, PA). 50 ul of the resuspended cells were seeded into 96-well plates at a density of 5,000-10,000 cells per well. Glutamine synthetase (GS)-positive transfectants were selected by addition of glutamine-free DMEM medium containing 10% dFCS, supplemented with 1 x GS (JRH Biosciences, Inc.) 24-h post-transfection. Cells were cultured for 2-4 weeks at 37 C, 5% CO2 to enable growth and expansion of colonies prior to screening for antibody-expressing clones.
[0129] Clones expressing anti-EGFR antibody were screened using a horseradish peroxidase anti-human Fc (gamma)-based ELISA and detection was carried out at A450nm.
Positive clones were expanded and retested over 3-5 days cultivation period.
Strong positives (antibody production of 25 _tL/mg or more) were expanded for further analysis.
Based on antibody batch production results of 249 [tg/mL, Clone #34 was selected for limiting dilution subcloning and reassessed. Clone 34-5 was selected based on consistent production levels, comparable to or better than the parent cell line (batch production = 310 Itg/mL, fed-batch = 0.75 ¨ 0.8 g/L). Clone #34-5-3 was isolated after a second round of subcloning and analysis showed that Clone #34-5-3 produces a high level of antibody (batch production = 324 g/mL, fed-batch = 1.0 ¨ 1.2 g/L). Further characterization of this clone was carried out in the following examples.
[0130] Example 5 - In Vitro Binding of Antibodies to EGFR.
[0131] Antibodies were screened in a solid state ELISA comparing the binding characteristics of IMC-11F8 and IMC-C225. Ninety six-well microtiter plate was coated overnight with 1 1.1g/mL in carbonate buffer at 4 C. Plates were blocked with phosphate buffered saline (PBS) supplemented with 10% new born calf serum for one hour at 37 C.
Various amounts of IIVIC-11F8 or IMC-C225 were added to the plates and incubated at room temperature for a further 60 minutes, followed by washing with PBS. Mouse anti-human Fc antibody-horse radish peroxidase (HRP) conjugate were added and incubated for an additional 60 minutes at room temperature, followed by extensive washing with PBS. The plate was then incubated with HRP substrate for 30 sec. ¨2 min. and the reaction stopped with 0.1 M H2SO4. The plates were read using an ELISA reader at OD450nrn=
[0132] Figure 3 shows the binding of IMC-11F8 and IMC-C225 antibodies to EGFR. Both IMC-11F8 and IMC-C225 exhibit comparable binding to EGFR.
[0133] Example 6- Binding Kinetics of Anti-EGFR Antibodies [0134] The binding kinetics of IMC-11F8 and IIVIC-C225 IgG antibodies and their respective Fab fragittents were measured using a BlAcore sensor (Pharmacia Biosensor, ) EGFR-AP fusion protein was immobilized onto a sensor chip and soluble IMC-l1F8 and EMC-C225 antibodies were injected at concentrations ranging from 1.5 uhf to 100 uhf.
Sensorgrams were obtained at each concentration and were analyzed with BIA
Evaluation 2.0, a program to determine the rate constants, lcu,, and koff. The affinity constant Kd, was calculated from the ratio of rate constants, Irodlro,, [0135] The binding kinetics of the anti-EGFR antibodies of the present invention are illustrated in Table 5. These show that both IgG antibodies have comparable binding kinetics to EGFR.
Antibody Format Icon (105 M4113 koff (leo lCd (nM) IMC-11F8 Fab 22.9 + 9.9 36.7 + 8.5 1.78 + 0.5:
IMC-11F8 IgG 18.6 + 7.7 5.8 + 2.2 0.32 + 0.06 IMC-C225 Fab 23.1 + 4.8 111 + 3.4 0.53 + 0.17 ]MC-C225 IgG 21.3 + 7.3 5.4 + 1.0 0.3 + 0.2 The results represent the mean + SE from at least three separate determinations.
[0136] Example 7 - Specificity of the Antibodies for EGFR
[0137] Antibody binding to EGFR was evaluated by a 1251-EGF competition assay.
HT29 cells were seeded at 2 x 104 cells per well in 24-well COSTAR plates (Fisher Scientific, U.S.A.) in McCoy's 5a medium supplemented with 1.5 mM L-glutamine, 10%
CS and antibiotics at 37 C. The cell monolayer was then incubated at room temperature for 1 hour with various concentrations of unlabeled EGF, 11F8 or 1MC-C225 that were mixed with various amounts of 12514abe1ed EGF. Cells were washed with cold PBS
and cell-associated radioactivity was measured in a gamma counter.
* Trade-mark [0138] Figure 4 shows the inhibition of 125I-EGF binding to EGFR on H1'29 cells.
At concentrations of between 10 to 100nM, INIC-11F8 is as efficient as IMC-C225 in inhibiting 1251-EGF binding to EGFR on HT29 cells. Both antibodies are better at competing for binding than EGF, the natural ligand of MFR. Similar results were observed for inhibition of 125I-EGF binding to EGFR on A431 cells.
[0139] Example 8- EGFR Activation [0140] Briefly, a lcinase receptor activation assay (KIRA assay), or phosphorylation assay, was carried out using ThcPC3 or A431 cells. Cells were first grown to 90% continency in DME supplemented with 4 triM leglutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose, 10% CS, at 37 C. Prior to experimentation, the cells were starved for 24 bin DME supplemented with 0.5% CS. To evaluate the effects of antibodies, Th4C-11F8,1MC-C225 and EVIC-1C11 on EGF-induced activation of EGFR, various concentrations of antibodies were prebound at room temperature for 30 minutes, followed by stimulation with EGF at 8 ng/mL for another 15 minutes.
Following stimulation, cell monolayers were washed with ice cold PBS containing 1 rnM
sodium orthovanadate. Cells were lysed in lysis buffer [20 mM Tric-HC1, pH. 7.4,1%
Triton X-100,137 mM NaCI, 10% glycerol, 10 mM EDTA, 2 mM sodium orthovanadate, 100 niM
NaF, 100 mM sodium pyrophosphate, 5 inM PEFABLOC SC (Boehringer Mannheim Biochemicals, Indianapolis, IN), 100 lig aprotinin and 100 itg/mL leupeptin]
and centrifuged at 14,000 x g for 10 minutes. Cleared cell lysates were added to wells of 96-well plates coated with polyclonal anti-EGFR antibody. The plates were washed to remove non-specifically bound proteins and the level of Et3FR phosphorylation was assessed by the addition of anti-phosphotyrosine antibody. Upon extensive washing, the amount of bound anti-phoshotyrosine antibody was measure using an BLISA reader at OD4sown-[0141] The results show a marked decrease in phosphorylation of FOR by RAC-1 IFS antibody in both BxPC3 (Figure 5) and A431 (Figure 6) cells tested as compared to control antibody, IMC-1C11.
[0142] Inhibition of FGF-stimulated EGFR phosphoryiation was further evaluated by Western blot analysis of the immunoprecipitatecl EGFR. A431 cells were prebound with antibodies followed by stimulation with EGF as described above. A control antibody that binds to EGFR but does not inhibit EGFR phosphorylation was used. Protein (EGFR) was immunoprecipitated from the cleared lysates using polyclonal anti-EGFR
antibody followed by Protein A Sepharosebeads. The bound-beads were then washed once with 0.2% Triton X-100, 10 mM Tris-HC1, pH 8.0,150 niM NaC1, 2 !TIM BDTA (Buffer A), twice with Buffer A containing 500 DWI NaC1 and twice with Tris-HCI, pH 8Ø
Drained beads were mixed with 30 ML 2 X SDS loading buffer, boiled and the supernatant was subjected to SDS-PAGE. After separation of proteins by electrophoresis, the protein bands were transferred onto nitrocellulose filters for Western Blot analysis.
Filters were blocked overnight in blocking buffer, 50 mM Tris-HC1, p117.4, 150 inM Neel (TBS) containing 5% bovine serum albumin and 10% nonfat dried milk. To detect phosphorylated receptor, blots were probed with an anti-phosphotyrosine antibody in blocking buffer for 1 hour at room temperature. Blots were then washed extensively with 0.5 x TBS containing 0.1% Tween-20 (TBS-T) and incubated with god anti-mouse Ig conjugated to HRP (Amersham, little Chalfont, UK). Blots were washed with TBS
and incubated for 1 minute with a chemilumineseence reagent (ECL, Junersham, Little Chalfont, U.K.). Anti-phosphotyrosine reacting with phosphorylated proteins was detected by exposure to a high performance luminescence detection film (Hyperfilm*-ECL, Amersham, Little Chalfont, U.K.) for 0.5 to 10 minutes.
[0143] Western blot analysis in Figure 7A shows that IMC-I1F8, like IMC-C225, inhibits EGFR phosphorylation. Neither EGF-antibody nor the control antibody-treated cells completely inhibits EGFR phosphorylation. Figure 7B shows that synthesis of EGFR
is not inhibited with the addition of antibodies to the cells. Figure 8 shows that phosphorylation of EGFR is inhibited by 1MC-11F8. Greater than 70% inhibition was observed for three tumor cell lines of different origin (A431, 13xPC3, HT-29) at the lowest antibody concentration tested (0.8 nM).
[0144] The effect of 1MC-11F8 on one of the major downstream signaling molecules of EGFR, MAP kinases p44442, was also examined. 1MC-11F8 blocked p44/42 MAP kinases phosphorylation following EGF stimulation in A431, BxPC3 and HT-29 cells in a dose-dependent manner (Fig. 4).
* Trade-mark [0145] Example 9 - Inhibition of Cell Proliferation [0146] The MTT Cell Proliferation Assay is measured color-metrically as a result of reduction of the yellow tetrazolium, MTT (3-(4, 5-dimethylthiazoly1-2)-2, 5-phenyltetrazolium bromide) by metabolically active cell to an intracellular purple formazan product, which can be solubilized and quantified by spectrophotometric means.
Briefly, DiFi cells were cultured overnight in DMEM-10% CS. Antibodies, IMC-11F8, IMC-C225 or IN4C-1C11 were added to triplicate wells and incubated for an additional 72 hours at 37 C, 5% CO2. To measure cell growth, a 20 1., aliquot of tetrazolium dye was added to each well and the cells were incubated for 3 hours at 37 C. When the purple precipitate was clearly visible under a microscope, the cells were lysed by addition of 100 pi detergent reagent. Absorbance of the formazan product was measured at OD57onm as a quantitation of proliferation.
[0147] As shown in Figure 9, unlike control antibody EVIC-1C11, IMC-11F8 is as potent an inhibitor of cell proliferation as IMC-C225.
[0148] Example 10 - Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity [0149] One method of assessing cell death is via an antibody dependent cell-mediated cytotoxicity assay or ADCC, which generally use the radioisotope 51Cr. Target cells labeled with 51Cr were mixed with antibody and the degree of killing was assessed by release of 51Cr. Briefly, approximately 3 x 106 DiFi cells were suspended in 0.5 ml culture medium and 0.5 mCi of Na51Cr04 was added. The mixture was incubated for 1 h at with occasional shaking. The cells were then washed three times with cold culture medium. The labeled cells were then suspended in 100 p.1 culture medium containing varying concentrations of anti-EGFR antibodies (IMC-11F8 or INIC-C225) and incubated for 30 minutes at 4 C. The cells were then washed three times with culture medium by centrifugation. Rabbit complement was added and the treated cells were further incubated at 37 C for 1 h. 50 pl of cold medium were then added and centrifuged. The supernatants were then removed and the radioactivity released by the cells into the supernatant was measured in a gamma counter. The maximum release of the radioactivity was obtained by adding 1% Triton X to the target cells. The percent cytotoxicity was calculated as cpm experimental release minus cpm background times 100%, which is then divided by the cpm maximum release minus rpm background.
[0150] Figure 10 shows IMC-11178 and 1A4C-C225 (or ERBrr(Jxe mediate cell death via activation of the Antibody Dependent Cellular Cytotoxicity or ADCC
activity).
[0151] Example 11 -In Vivo Inhibition of Tumor Cell Growth in Mice [0152] In vivo anti-tumor studies were designed to determine if1MC-11F8 would block the growth of tumor cells in a xenograft model. Athymic mice (nu/nu;
Charles River Lab, Wilmington. MA) were injected subcutaneously with 1-2 million A431 or Bx.PC-3 cells in the flank. Anti-FsGFR antibodies (Th4C-11F8 and 1MC-C225) or control antibody was administered intraperitoneally at either 1 mg/dose or 0.3 mg/dose, three times per week. Tumor size was measured at least three times per week with a caliper and tumor volume calculated (See, e.g. Baselga at aL, J Natl. Cancer hist (1993) 85:1327-1333) [0153] Figure 11 shows the anti-tumor activity of IMC-11F8 in A431 xenograft model At 1 mg dose (Figure 11, right panel, TMC-11F8 is as effective as IMC-(CETUXEMAB) in suppressing or inhibiting tumor growth as compared to control animals. At a lower dose of 0.3 mg, progression of tumor growth is retarded.
Similarly, Figure 12 shows the effect of1MC-11F8 and 1MC-C225 in a second tumor model (BxPC-3 xenograft). The kinetics of Ifx.PC3 tumor growth is similar to that observed in the A431 tumor model. At the 1.0 mg/mouse/injection dose level IMC-1 IFS led to 6 tumor regressions out of 8 A413-bearing animals, and 5 tumor regression out of 8 13xPC3-bearing mice.
[0154] Immunolistochemistry staining of both A431 and BxPC3 xenograft sections revealed that DvIC-11F8 treatment markedly reduced the tumor cell density and increased the area of necrotic acellular debris within the tumors (Fig. 13).
Further, IMC-11F8 reduced the percentage of Ki-67 positive cells across the entire tumor section, indicating a reduction in cell proliferation within the tumors (F18. 13).
(01551 Example 12¨ IMC.11Fil Combination Therapy [0156] Nude mice bearing human colorectal tumor xenografts, GEO, DLD-1, or HT-29, of approximately 200-300 mm3 were treated by interperitoneal injection of IMC-11F8 twice a week at 0.3 mg or 1.0 mg/injection, alone or in combination with irinotecan (CPT-11) at a dose of 100 mg/kg once a week. Tumor sizes were measured twice a week.
[0157] Treatment with IMC-11F8 at either 0.3 mg or 1.0 mg/mouse/injection significantly inhibited the growth of all three colorectal xenografts (GEO, DLD-1, or HT-29; Fig. 14A-C). When administered to mice bearing GEO xenografts in combination with CPT-11, IMC-11F8 significantly increased the tumor growth inhibition observed with CPT-11 alone (Fig. 14A; p<0.01 for both doses of IMC-11F8). Moreover while CPT-11 alone caused no tumor regressions in this model, 4 out of 10 and 9 out of 10 tumor regressions were achieved when CPT-11 was combined with IMC-11F8 at 0.3 mg or 1.0 mg/mouse/injection, respectively (p = 0.004 and p<0.0001, respectively). Similar combinational anti-tumor effects were observed in two other xenografts, DLD-1 (Fig.
14B) and HT-29 (Fig. 14C) with equivalent statistical significance in tumor regression in the higher antibody dose (1.0 mg) group. Fig. 14D illustrates the significant increase in the number of tumor regressions observed when CPT-11 is combined with IMC-11F8 in these three colorectal carcinoma xenografts models.
[0158] Example 13 ¨ Pharmacokinetics of IMC-11F8 [0159] The pharmacokinetics of lIVIC-11F8 was studied in cynomolgus monkeys and compared to the pharmacokinetics of IMC-C225. A single dose pharmacokinetic study at 20.5 mg/kg 1251-radio-labeled IMC-11F8 and IMC-C225 was separately injected intravenously in monkey and blood was drawn at day to determine the level of antibody that is retained in the plasma of the animal. Table 6 provides a pharmacokinetics comparison of IMC-11F8 and IMC-C225 in cynomolgus monkeys.
Caux (n18/1-) 1213 1161 Timx (hrs) 0.75 0.117 Tin (bra) 116 117 AUC (mg*br/L) 115400 97871 CI (n.L/br) 0.736 0.636 [0160] It will be understood by one skilled in the art that the scope of the claims should not be limited by the preferred embodiment or examples but should be given the broadest interpretation consistent with the description as a whole.
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.
NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
NOTE: For additional volumes please contact the Canadian Patent Office.
Claims (51)
1. An isolated human antibody or antibody fragment that specifically binds to epidermal growth factor receptor (EGFR) consisting of complementarity determining regions of SEQ ID NO-2 at CDRH1, SEQ ID NO:4 at CDRH2, SEQ ID NO:6 at CDRH3, SEQ ID NO.10 at CDRL1; SEQ ID NO12 at CDRL2; and SEQ ID NO:14 at
2. The antibody or antibody fragment of Claim 1, which comprises a heavy chain variable region of SEQ ID NO.8 and a light chain variable region of SEQ ID
NO.16.
NO.16.
3. The antibody or antibody fragment of Claims 1 or 2, which binds selectively to EGFR.
4. The antibody or antibody fragment of Claims 1 or 2, which inhibits binding of EGFR to a ligand of EGFR
5. The antibody or antibody fragment of Claims 1 or 2, which neutralizes EGFR.
6 The antibody or antibody fragment of Claim 1 or 2, which inhibits phosphorylation of EGFR.
7 The antibody or antibody fragment of Claim 1 or 2, which inhibits cell proliferation
8. The antibody or antibody fragment of Claim 1 or 2, which mediates cell death via activation of antibody dependent cellular cytotoxicity (ADCC) activity.
9 The antibody of any one of Claims 1 to 8 wherein the antibody is an immunoglobulin G antibody
The antibody of any one of Claims 1 to 9, wherein the antibody is an IgG1 antibody.
11. An isolated polynucleotide which encodes an antibody of any one of Claims 1 to 10.
12. An expression vector comprising the polynucleotide of Claim 11
13. A recombinant host cell which produces an antibody encoded by the isolated polynucleotide of Claim 11.
14. Use of the antibody or antibody fragment as defined in any one of Claims 1 to for inhibiting tumor growth in a mammal in need thereof.
15. The use of Claim 14, wherein the tumor is a colorectal tumor.
16. The use of Claim 14, wherein the tumor is a pancreatic tumor.
17. The use of Claim 14, wherein the tumor is an epithelial tumor.
18. Use of the antibody or antibody fragment as defined in any one of Claims 1 to 10 for treating tumor growth in a mammal in need thereof.
19. The use of Claim 18, wherein the tumor is a colorectal tumor.
20. The use of Claim 18, wherein the tumor is a pancreatic tumor.
21. The use of Claim 18, wherein the tumor is an epithelial tumor.
22. Use of the antibody or antibody fragment as defined in any one of Claims 1 to 10 for the treatment of lung cancer.
23. Use of the antibody or antibody fragment as defined in any one of Claims 1 to 10 for the treatment of non-small cell lung cancer (NSCLC).
24. Use of the antibody or antibody fragment as defined in any one of Claims 1 to 10 for the treatment of squamous non-small cell lung cancer (NSCLC).
25. Use of the antibody or antibody fragment as defined in any one of Claims 1 to 10 for the treatment of head and neck cancer.
26. Use of the antibody or antibody fragment as defined in any one of Claims 1 to 10 for the inhibition of lung cancer.
27. Use of the antibody or antibody fragment as defined in any one of Claims 1 to 10 for the inhibition of non-small cell lung cancer (NSCLC).
28. Use of the antibody or antibody fragment as defined in any one of Claims 1 to 10 for the inhibition of squamous non-small cell lung cancer (NSCLC).
29. Use of the antibody or antibody fragment as defined in any one of Claims 1 to for the inhibition of head and neck cancer.
30. The use of any one of Claims 14 to 29, wherein the antibody or antibody fragment is used in combination with an anti-neoplastic agent.
31. The use of Claim 30, wherein the antineoplastic agent is a chemotherapeutic agent.
32. The use of Claim 31, wherein the antineoplastic agent is irinotecan (CPT-11).
33. Use of the antibody or antibody fragment as defined in any one of Claims 1 to 10 for manufacture of a medicament for inhibiting tumor growth in a mammal in need thereof.
34. The use of Claim 33, wherein the tumor is a colorectal tumor.
35. The use of Claim 33, wherein the tumor is a pancreatic tumor.
36. The use of Claim 33, wherein the tumor is an epithelial tumor.
37. Use of the antibody or antibody fragment as defined in any one of Claims 1 to 10 for manufacture of a medicament for treating tumor growth in a mammal in need thereof.
38. The use of Claim 37, wherein the tumor is a colorectal tumor.
39. The use of Claim 37, wherein the tumor is a pancreatic tumor.
40. The use of Claim 37, wherein the tumor is an epithelial tumor.
41. Use of the antibody or antibody fragment as defined in any one of Claims 1 to 10 for manufacture of a medicament for the treatment of lung cancer.
42. Use of the antibody or antibody fragment as defined in any one of Claims 1 to 10 for manufacture of a medicament for the treatment of non-small cell lung cancer (NSCLC).
43. Use of the antibody or antibody fragment as defined in any one of Claims 1 to for manufacture of a medicament for the treatment of squamous non-small cell lung cancer (NSCLC).
44. Use of the antibody or antibody fragment as defined in any one of Claims 1 to 10 for the manufacture of a medicament for the treatment of head and neck cancer.
45. Use of the antibody or antibody fragment as defined in any one of Claims 1 to 10 for manufacture of a medicament for the inhibition of lung cancer.
46. Use of the antibody or antibody fragment as defined in any one of Claims 1 to 10 for manufacture of a medicament for the inhibition of non-small cell lung cancer (NSCLC).
47. Use of the antibody or antibody fragment as defined in any one pf Claims 1 to 10 for manufacture of a medicament for the inhibition of squamous non-small cell lung cancer (NSCLC).
48. Use of the antibody or antibody fragment as defined in any one of Claims 1 to 10 for the manufacture of a medicament for the inhibition of head and neck cancer.
49. The use of any one of Claims 33 to 48, wherein the antibody or antibody fragment is used in combination with an anti-neoplastic agent.
50. The use of Claim 49, wherein the antineoplastic agent is a chemotherapeutic agent.
51. The use of Claim 50, wherein the antineoplastic agent is irinotecan (CPT-11).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55455504P | 2004-03-19 | 2004-03-19 | |
US60/554,555 | 2004-03-19 | ||
US62426404P | 2004-11-02 | 2004-11-02 | |
US60/624,264 | 2004-11-02 | ||
PCT/US2005/009583 WO2005090407A1 (en) | 2004-03-19 | 2005-03-21 | Human anti-epidermal growth factor receptor antibody |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2560305A1 CA2560305A1 (en) | 2005-09-29 |
CA2560305C true CA2560305C (en) | 2016-07-05 |
Family
ID=34964896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2560305A Expired - Fee Related CA2560305C (en) | 2004-03-19 | 2005-03-21 | Human anti-epidermal growth factor receptor antibody |
Country Status (18)
Country | Link |
---|---|
US (1) | US7598350B2 (en) |
EP (2) | EP2332990A1 (en) |
JP (1) | JP4734319B2 (en) |
CN (1) | CN103007279B (en) |
AU (1) | AU2005224267B2 (en) |
CA (1) | CA2560305C (en) |
CY (2) | CY1113037T1 (en) |
DK (1) | DK1735348T3 (en) |
ES (1) | ES2387809T3 (en) |
HU (1) | HUS000495I2 (en) |
LT (1) | LTC1735348I2 (en) |
LU (1) | LU93093I2 (en) |
MX (1) | MXPA06010715A (en) |
NL (1) | NL300819I2 (en) |
PL (1) | PL1735348T3 (en) |
PT (1) | PT1735348E (en) |
RU (1) | RU2402569C2 (en) |
WO (1) | WO2005090407A1 (en) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US20030224001A1 (en) * | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
BR0010524A (en) * | 1999-05-14 | 2002-05-28 | Imclone Systems Inc | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
JP2004527456A (en) * | 2000-08-09 | 2004-09-09 | イムクローン システムズ インコーポレイティド | Treatment of hyperproliferative diseases with EGF receptor antagonists |
US20080008704A1 (en) * | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
JP2006524036A (en) * | 2002-11-08 | 2006-10-26 | アブリンクス エン.ヴェー. | Single domain antibodies targeting tumor necrosis factor alpha and uses thereof |
CN102584997A (en) * | 2002-11-08 | 2012-07-18 | 埃博灵克斯股份有限公司 | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
US20060034845A1 (en) * | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
US20100003253A1 (en) * | 2002-11-08 | 2010-01-07 | Ablynx N.V. | Single domain antibodies directed against epidermal growth factor receptor and uses therefor |
AU2003286003B2 (en) * | 2002-11-08 | 2011-05-26 | Ablynx N.V. | Stabilized single domain antibodies |
EP1622941A2 (en) * | 2003-03-20 | 2006-02-08 | ImClone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
CA2641310C (en) * | 2006-02-03 | 2013-08-20 | Imclone Systems Incorporated | Igf-ir antagonists as adjuvants for treatment of prostate cancer |
CN101058609B (en) * | 2006-05-26 | 2011-04-13 | 神州细胞工程有限公司 | Human antibody and expression thereof |
WO2007147001A2 (en) * | 2006-06-14 | 2007-12-21 | Imclone Systems Incorporated | Lyophilized formulations of anti-egfr antibodies |
CA2664327A1 (en) * | 2006-09-15 | 2008-03-20 | Lifescience Pharmaceuticals | Method for detecting and treating skin disorders |
US7820159B2 (en) * | 2006-10-31 | 2010-10-26 | Instiute of Virology of the Slovak Academy of Sciences | MN/CA IX and EGFR pathway inhibition |
WO2009067242A2 (en) * | 2007-11-20 | 2009-05-28 | Imclone Llc | Co-crystal of antibody 11f8 fab fragment and egfr extracellular domain and uses thereof |
AU2008346734A1 (en) * | 2008-01-03 | 2009-07-16 | The Scripps Research Institute | Antibody targeting through a modular recognition domain |
AU2009215503B2 (en) * | 2008-02-20 | 2014-05-08 | Arizona Cancer Therapeutics, Llc | Use of therapeutic peptides for the treatment and prevention of cancer |
ES2570731T3 (en) | 2008-08-05 | 2016-05-20 | Toray Industries | Cancer screening method |
ES2502940T3 (en) | 2008-08-05 | 2014-10-06 | Toray Industries, Inc. | Pharmaceutical composition for the treatment and prevention of cancer |
RU2636046C2 (en) | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Modified antibodies composition, methods of production and application |
KR101108642B1 (en) * | 2009-09-29 | 2012-02-09 | 주식회사 녹십자 | Antibodies specifically binding to the epidermal growth factor receptor |
CN101875695B (en) * | 2009-11-11 | 2012-07-04 | 中国人民解放军军事医学科学院生物工程研究所 | Antibody, and coding gene and application thereof |
CN101875696B (en) | 2009-11-11 | 2012-02-08 | 中国人民解放军军事医学科学院生物工程研究所 | Antibody, and preparation method and application thereof |
CN101704891B (en) | 2009-11-11 | 2011-11-09 | 中国人民解放军军事医学科学院生物工程研究所 | Antibody for epidermal growth factor receptor, encoding gene thereof and application thereof |
SG181707A1 (en) * | 2009-12-18 | 2012-07-30 | Sanofi Sa | Novel antagonist antibodies and their fab fragments against gpvi and uses thereof |
MX342291B (en) | 2010-02-04 | 2016-09-23 | Toray Industries | Pharmaceutical composition for treatment and/or prevention of cancer. |
HUE030102T2 (en) | 2010-02-04 | 2017-04-28 | Toray Industries | Pharmaceutical composition comprising anti caprin-1 antibodies for treating and/or preventing cancer |
CN109925511B (en) | 2010-02-04 | 2024-03-19 | 东丽株式会社 | Medicine for treating and/or preventing cancer |
CA2788715C (en) | 2010-02-04 | 2021-06-08 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
EP2532743B1 (en) | 2010-02-04 | 2015-04-15 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
WO2012018260A1 (en) * | 2010-08-05 | 2012-02-09 | Universiteit Utrecht Holding B.V. | Epidermal growth factor receptor targeted immune therapy |
WO2012033953A1 (en) | 2010-09-08 | 2012-03-15 | Halozyme, Inc. | Methods for assessing and identifying or evolving conditionally active therapeutic proteins |
KR101273918B1 (en) | 2010-09-17 | 2013-06-13 | 강원대학교산학협력단 | A human anti-epidermal growth factor receptor Fab antibody and a pharmaceutical composition for treating tumor comprising the same |
JP2013544237A (en) | 2010-10-12 | 2013-12-12 | アリゾナ バイオメディカル リサーチ コミッション | EGFR-based peptides |
CN103298489A (en) | 2010-10-29 | 2013-09-11 | 伊缪诺金公司 | Novel EGFR-binding molecules and immunoconjugates thereof |
EP2632947A4 (en) | 2010-10-29 | 2015-03-18 | Immunogen Inc | Non-antagonistic egfr-binding molecules and immunoconjugates thereof |
EP2670426B1 (en) | 2011-01-31 | 2017-05-10 | The General Hospital Corporation | Multimodal trail molecules and uses in cellular therapies |
WO2012143499A2 (en) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Novel binder-drug conjugates (adcs) and their use |
EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
BR112014002619A2 (en) | 2011-08-04 | 2018-10-09 | Toray Industries, Inc | pharmaceutical composition and method of treatment and / or prevention of pancreatic cancer and pharmaceutical combination |
DK2740798T3 (en) | 2011-08-04 | 2017-03-06 | Toray Industries | Drug composition for cancer treatment and / or prevention |
AU2012290957B2 (en) | 2011-08-04 | 2017-04-20 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
JP6065591B2 (en) | 2011-08-04 | 2017-01-25 | 東レ株式会社 | Pharmaceutical composition for treatment and / or prevention of cancer |
MX348579B (en) | 2011-08-04 | 2017-06-20 | Toray Industries | Drug composition for cancer treatment and/or prevention. |
RU2624040C2 (en) | 2011-08-04 | 2017-06-30 | Торэй Индастриз, Инк. | Method for pancreatic cancer detection |
DK2740794T3 (en) | 2011-08-04 | 2018-06-14 | Toray Industries | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR CANCER PREVENTION |
KR20140105765A (en) | 2011-11-21 | 2014-09-02 | 이뮤노젠 아이엔씨 | Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
IN2014KN01715A (en) | 2012-02-21 | 2015-10-23 | Toray Industries | |
CA2864864C (en) | 2012-02-21 | 2020-05-12 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
BR112014021099A2 (en) | 2012-02-21 | 2020-12-01 | Toray Industries, Inc | antibody, pharmaceutical composition, DNA and method of treatment and / or prevention of cancer and use of an antibody |
AU2013223147B2 (en) | 2012-02-21 | 2017-10-05 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
EP3296320A1 (en) | 2012-03-08 | 2018-03-21 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
PT2832365T (en) | 2012-03-30 | 2018-01-24 | Toray Industries | Pharmaceutical composition for treatment and/or prevention of liver cancer |
JP6107655B2 (en) | 2012-03-30 | 2017-04-05 | 東レ株式会社 | Pharmaceutical composition for treatment and / or prevention of gallbladder cancer |
CA2872018A1 (en) * | 2012-05-17 | 2013-11-21 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind egfr |
JP6103832B2 (en) | 2012-06-25 | 2017-03-29 | Hoya株式会社 | EGFR binding peptide |
ES2718348T3 (en) | 2012-07-19 | 2019-07-01 | Toray Industries | Method to detect cancer |
PT2876447T (en) | 2012-07-19 | 2020-02-03 | Toray Industries | Method for detecting cancer |
EP2877572B1 (en) | 2012-07-24 | 2018-11-28 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
JP6324381B2 (en) | 2012-07-31 | 2018-05-16 | クラウン バイオサイエンス インコーポレイテッド(タイカン) | Histological marker for identifying patients with non-small cell lung cancer for treatment with anti-EGFR drugs |
US9605074B2 (en) * | 2012-08-30 | 2017-03-28 | The General Hospital Corporation | Multifunctional nanobodies for treating cancer |
CN102993305B (en) * | 2012-11-16 | 2015-05-13 | 上海赛伦生物技术有限公司 | Humanized anti-human epidemic growth factor receptor (EGFR) antibody as well as encoding gene and application thereof |
WO2014166029A1 (en) | 2013-04-07 | 2014-10-16 | 永卓博济(上海)生物医药技术有限公司 | Epidermal growth factor receptor antibody |
US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
AU2014303375B2 (en) | 2013-08-09 | 2019-07-04 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
MX2016003256A (en) | 2013-09-12 | 2016-06-07 | Halozyme Inc | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof. |
CN113402609B (en) * | 2013-12-20 | 2023-12-05 | 英特维特国际股份有限公司 | Canine antibodies with modified CH2-CH3 sequences |
SG11201604758PA (en) | 2013-12-23 | 2016-07-28 | Bayer Pharma AG | Antibody drug conjugates (adcs) with kinesin spindel protein (ksp) |
SG11201606791YA (en) | 2014-03-03 | 2016-09-29 | Academia Sinica | Bi-specific antibodies and uses thereof |
JP6706244B2 (en) * | 2014-07-24 | 2020-06-03 | ブルーバード バイオ, インコーポレイテッド | BCMA chimeric antigen receptor |
CN105315371B (en) * | 2015-03-05 | 2018-05-29 | 北京百特美博生物科技有限公司 | Anti-human IL-17 monoclonal antibodies |
WO2016161440A2 (en) | 2015-04-03 | 2016-10-06 | Arizona Cancer Therapeutics, Llc | Egfr-based inhibitor peptides for combinatorial inactivation of erbb1, erbb2, and erbb3 |
TW201703769A (en) | 2015-05-08 | 2017-02-01 | 美國禮來大藥廠 | Combination therapy for cancer |
MX2017017172A (en) | 2015-06-22 | 2018-02-23 | Bayer Pharma AG | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups. |
KR20180020225A (en) | 2015-06-23 | 2018-02-27 | 바이엘 파마 악티엔게젤샤프트 | Targeted conjugates of KSP inhibitors |
TW201716439A (en) | 2015-07-20 | 2017-05-16 | 美國禮來大藥廠 | HER3 antibodies |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
WO2017160568A1 (en) | 2016-03-16 | 2017-09-21 | Eli Lilly And Company | Combination therapy comprising the cdk4/6 inhibitor necitumumab and the egfr inhibitor abemaciclib for use in treating cancer |
WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
SG11201808167VA (en) | 2016-03-24 | 2018-10-30 | Bayer Pharma AG | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
JP7022707B2 (en) | 2016-06-15 | 2022-02-18 | バイエル・ファルマ・アクティエンゲゼルシャフト | Specific antibody-drug-conjugate (ADC) including KSP inhibitor and anti-CD123 antibody |
EP3515940A1 (en) * | 2016-09-26 | 2019-07-31 | ImClone LLC | Combination therapy for cancer |
WO2018114578A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) having enzymatically cleavable groups |
CN110312533B (en) | 2016-12-21 | 2023-11-03 | 拜耳公司 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
CA3047522A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (adcs) having ksp inhibitors |
JP7072792B2 (en) * | 2017-12-11 | 2022-05-23 | 国立大学法人神戸大学 | Bispecific antibody |
EP3883610A4 (en) | 2018-11-20 | 2022-11-02 | Cornell University | Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer |
WO2020132574A1 (en) * | 2018-12-21 | 2020-06-25 | CentryMed Pharmaceutical Inc. | Protease cleavable bispecific antibodies and uses thereof |
EP4045641A1 (en) | 2019-10-15 | 2022-08-24 | Eli Lilly and Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
CN117003868B (en) * | 2020-04-17 | 2024-04-16 | 珠海泰诺麦博制药股份有限公司 | Antibodies against human nerve growth factor |
EP4192503A2 (en) * | 2020-08-05 | 2023-06-14 | Ohio State Innovation Foundation | Adapter polypeptides and methods of using the same |
JP2023545681A (en) | 2020-09-30 | 2023-10-31 | インスティテュート オブ ズーオロジー、チャイニーズ アカデミー オブ サイエンシーズ | Chimeric antigen receptor targeting EGFR |
WO2022140670A2 (en) * | 2020-12-23 | 2022-06-30 | Phenomic Ai | Anti-activin antibodies and methods of using the same |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (en) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE |
FR2388385B1 (en) * | 1977-04-18 | 1982-01-08 | Hitachi Metals Ltd | ORNAMENT FIXED BY PERMANENT MAGNETS |
US4510924A (en) * | 1980-07-10 | 1985-04-16 | Yale-New Haven Hospital, Inc. | Brachytherapy devices and methods employing americium-241 |
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4943533A (en) * | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US5866363A (en) * | 1985-08-28 | 1999-02-02 | Pieczenik; George | Method and means for sorting and identifying biological information |
US4816401A (en) * | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
CA1275922C (en) * | 1985-11-28 | 1990-11-06 | Harunobu Amagase | Treatment of cancer |
US4846782A (en) * | 1986-03-14 | 1989-07-11 | Schering Corporation | Treatment of cancer with interferon and radiotherapy |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4763642A (en) * | 1986-04-07 | 1988-08-16 | Horowitz Bruce S | Intracavitational brachytherapy |
US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
ATE120761T1 (en) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | MULTIFUNCTIONAL PROTEINS WITH PREDEFINED TARGET. |
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5470571A (en) * | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
DE68921364T2 (en) | 1988-04-16 | 1995-06-29 | Celltech Ltd | Process for the production of proteins using recombinant DNA. |
AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
CA2063431C (en) * | 1989-07-06 | 2002-10-29 | Lewis T. Williams | Receptors for fibroblast growth factors |
US5705157A (en) * | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5196446A (en) * | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
IL97872A (en) | 1990-04-16 | 1996-07-23 | Rhone Poulenc Rorer Int | Pharmaceutical compositions containing styryl-substituted monocylic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase and a compounds of this type |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JP3854306B2 (en) * | 1991-03-06 | 2006-12-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Humanized and chimeric monoclonal antibodies |
US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
ES2206447T3 (en) * | 1991-06-14 | 2004-05-16 | Genentech, Inc. | HUMANIZED ANTIBODY FOR HEREGULINE. |
IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
ES2136092T3 (en) * | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
US5559235A (en) * | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
DK1024191T3 (en) * | 1991-12-02 | 2008-12-08 | Medical Res Council | Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries |
AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
JP3720353B2 (en) * | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | Multivalent and multispecific binding proteins, their production and use |
US5855885A (en) * | 1993-01-22 | 1999-01-05 | Smith; Rodger | Isolation and production of catalytic antibodies using phage technology |
US5550114A (en) * | 1993-04-02 | 1996-08-27 | Thomas Jefferson University | Epidermal growth factor inhibitor |
US5654307A (en) * | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
US6811779B2 (en) * | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
US6448077B1 (en) * | 1994-02-10 | 2002-09-10 | Imclone Systems, Inc. | Chimeric and humanized monoclonal antibodies specific to VEGF receptors |
US5840301A (en) * | 1994-02-10 | 1998-11-24 | Imclone Systems Incorporated | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
US5861499A (en) | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
CZ288955B6 (en) * | 1994-02-23 | 2001-10-17 | Pfizer Inc. | Substituted quinazoline derivatives, their use and pharmaceutical preparations based thereon |
WO1995024190A2 (en) * | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
PT699237E (en) * | 1994-03-17 | 2003-07-31 | Merck Patent Gmbh | ANTI-EGFR CHAIN FVS AND ANTI-EGFR ANTIBODIES |
JP3249007B2 (en) * | 1994-03-17 | 2002-01-21 | 富士通株式会社 | Semiconductor device, characteristic evaluation method and design method thereof |
US5656655A (en) * | 1994-03-17 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase |
US5869465A (en) * | 1994-04-08 | 1999-02-09 | Receptagen Corporation | Methods of receptor modulation and uses therefor |
US5468754A (en) * | 1994-04-19 | 1995-11-21 | Bionumerik Pharmaceuticals, Inc. | 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof |
US5604233A (en) * | 1994-04-28 | 1997-02-18 | Bionumerik Pharmaceuticals, Inc. | Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof |
US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
EP2295415A1 (en) | 1995-03-30 | 2011-03-16 | OSI Pharmaceuticals, Inc. | Quinazoline derivatives |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5663144A (en) * | 1995-05-03 | 1997-09-02 | The Trustees Of The University Of Pennsylvania | Compounds that bind to p185 and methods of using the same |
US5726181A (en) * | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
AU1441497A (en) | 1996-01-23 | 1997-08-20 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
AU3305197A (en) * | 1996-06-06 | 1998-01-05 | University Of Massachusetts | Non-activated receptor complex proteins and uses thereof |
EP0907642B1 (en) | 1996-06-24 | 2005-11-02 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
US6004967A (en) * | 1996-09-13 | 1999-12-21 | Sugen, Inc. | Psoriasis treatment with quinazoline compounds |
EP0964864B1 (en) | 1997-02-05 | 2008-04-09 | Warner-Lambert Company LLC | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
US5942602A (en) * | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
US20030105057A1 (en) * | 1997-03-19 | 2003-06-05 | Yale University | Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment |
US5914269A (en) * | 1997-04-04 | 1999-06-22 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of epidermal growth factor receptor expression |
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US20020173629A1 (en) * | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
US6417168B1 (en) * | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
MXPA00011248A (en) * | 1998-05-15 | 2004-09-06 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
BR9914167B1 (en) | 1998-09-29 | 2011-03-09 | pharmaceutical compounds and compositions comprising substituted 3-cyano quinolines. | |
ES2188254T3 (en) | 1998-11-19 | 2003-06-16 | Warner Lambert Co | N- (4- (3-CHLORO-4-FLUORO-PHENYLAMINE) -7- (3-MORFOLIN-4-IL-PROPOXI) -QUIN AZOLIN-6-IL) -ACRILAMADA, AN IRREVERSIBLE THYROSINE KINASE INHIBITOR. |
US7396810B1 (en) * | 2000-08-14 | 2008-07-08 | Oregon Health Sciences University | Compositions and methods for treating cancer by modulating HER-2 and EGF receptors |
BR0010524A (en) * | 1999-05-14 | 2002-05-28 | Imclone Systems Inc | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
DK2067788T3 (en) | 1999-05-18 | 2015-10-19 | Dyax Corp | Fab fragment libraries and methods for using them |
ES2330301T3 (en) * | 1999-08-27 | 2009-12-09 | Genentech, Inc. | DOSAGES FOR TREATMENT WITH ANTI-ERBB2 ANTIBODIES. |
JP2004527456A (en) * | 2000-08-09 | 2004-09-09 | イムクローン システムズ インコーポレイティド | Treatment of hyperproliferative diseases with EGF receptor antagonists |
AU2002211658A1 (en) * | 2000-10-13 | 2002-04-22 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
WO2002045653A2 (en) * | 2000-12-08 | 2002-06-13 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
US20040116330A1 (en) * | 2001-04-27 | 2004-06-17 | Kenichiro Naito | Preventive/therapeutic method for cancer |
CN100497389C (en) * | 2001-06-13 | 2009-06-10 | 根马布股份公司 | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
DE10163459A1 (en) * | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilized preparation containing antibodies to EGF receptor |
AU2003224604B2 (en) * | 2002-01-28 | 2007-06-14 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (PSMA) |
ATE475431T1 (en) | 2002-03-04 | 2010-08-15 | Imclone Llc | KDR-SPECIFIC HUMAN ANTIBODIES AND THEIR APPLICATION |
ES2359136T3 (en) * | 2002-03-08 | 2011-05-18 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | USE OF EGFR TRANSACTIVATION INHIBITORS IN HUMAN CANCER. |
DE60326226D1 (en) * | 2002-03-21 | 2009-04-02 | Cayman Chemical Co | PROSTAGLANDIN F2 ALPHA ANALOGUE IN COMBINATION WITH AN ANTIMICROBIAL AGENT FOR THE TREATMENT OF GLAUCOMA |
WO2003101491A1 (en) * | 2002-06-03 | 2003-12-11 | Mitsubishi Pharma Corporation | PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR |
AU2003251791B2 (en) * | 2002-07-03 | 2009-07-23 | The Trustees Of The University Of Pennsylvania | Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof |
EP1549345A1 (en) * | 2002-10-10 | 2005-07-06 | MERCK PATENT GmbH | Bispecific anti-erb-b antibodies and their use in tumor therapy |
WO2005044858A1 (en) * | 2003-11-07 | 2005-05-19 | Ablynx N.V. | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
WO2005016970A2 (en) | 2003-05-01 | 2005-02-24 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
EP1493445A1 (en) * | 2003-07-04 | 2005-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of stress-induced ligand-dependent EGFR activation |
DE10355904A1 (en) * | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Solid forms of anti-EGFR antibodies |
RU2390353C2 (en) * | 2004-02-12 | 2010-05-27 | Мерк Патент Гмбх | High-concentration liquid anti-egfr antibody compositions |
TW200533339A (en) * | 2004-03-16 | 2005-10-16 | Bristol Myers Squibb Co | Therapeutic synergy of anti-cancer compounds |
PE20070207A1 (en) * | 2005-07-22 | 2007-03-09 | Genentech Inc | COMBINED TREATMENT OF TUMORS THAT EXPRESS HER |
JP5835204B2 (en) | 2012-12-20 | 2015-12-24 | 信越化学工業株式会社 | Resist material and pattern forming method using the same |
-
2005
- 2005-03-21 ES ES05732383T patent/ES2387809T3/en active Active
- 2005-03-21 RU RU2006137060/13A patent/RU2402569C2/en not_active IP Right Cessation
- 2005-03-21 US US10/593,804 patent/US7598350B2/en active Active
- 2005-03-21 PL PL05732383T patent/PL1735348T3/en unknown
- 2005-03-21 CA CA2560305A patent/CA2560305C/en not_active Expired - Fee Related
- 2005-03-21 AU AU2005224267A patent/AU2005224267B2/en not_active Ceased
- 2005-03-21 MX MXPA06010715A patent/MXPA06010715A/en active IP Right Grant
- 2005-03-21 JP JP2007504185A patent/JP4734319B2/en active Active
- 2005-03-21 WO PCT/US2005/009583 patent/WO2005090407A1/en active Application Filing
- 2005-03-21 CN CN201210509997.4A patent/CN103007279B/en not_active Expired - Fee Related
- 2005-03-21 PT PT05732383T patent/PT1735348E/en unknown
- 2005-03-21 EP EP10176938A patent/EP2332990A1/en not_active Withdrawn
- 2005-03-21 EP EP05732383A patent/EP1735348B1/en active Active
- 2005-03-21 DK DK05732383.4T patent/DK1735348T3/en active
-
2012
- 2012-08-06 CY CY20121100704T patent/CY1113037T1/en unknown
-
2016
- 2016-05-20 CY CY2016016C patent/CY2016016I1/en unknown
- 2016-05-31 LU LU93093C patent/LU93093I2/en unknown
- 2016-06-01 LT LTPA2016020C patent/LTC1735348I2/en unknown
- 2016-06-14 HU HUS1600030C patent/HUS000495I2/en unknown
- 2016-06-14 NL NL300819C patent/NL300819I2/nl unknown
Also Published As
Publication number | Publication date |
---|---|
HUS000495I2 (en) | 2021-03-29 |
EP1735348A1 (en) | 2006-12-27 |
CN103007279A (en) | 2013-04-03 |
LTC1735348I2 (en) | 2017-11-10 |
HUS1600030I1 (en) | 2016-07-28 |
CN103007279B (en) | 2017-01-11 |
PL1735348T3 (en) | 2012-11-30 |
CA2560305A1 (en) | 2005-09-29 |
US7598350B2 (en) | 2009-10-06 |
CY2016016I2 (en) | 2016-12-14 |
RU2402569C2 (en) | 2010-10-27 |
ES2387809T3 (en) | 2012-10-02 |
AU2005224267B2 (en) | 2011-07-21 |
NL300819I2 (en) | 2016-07-21 |
LU93093I2 (en) | 2016-08-01 |
RU2006137060A (en) | 2008-04-27 |
EP1735348B1 (en) | 2012-06-20 |
CY1113037T1 (en) | 2016-04-13 |
CY2016016I1 (en) | 2016-12-14 |
US20070264253A1 (en) | 2007-11-15 |
DK1735348T3 (en) | 2012-07-16 |
AU2005224267A1 (en) | 2005-09-29 |
JP2008500815A (en) | 2008-01-17 |
JP4734319B2 (en) | 2011-07-27 |
WO2005090407A8 (en) | 2005-12-01 |
WO2005090407A1 (en) | 2005-09-29 |
MXPA06010715A (en) | 2007-05-23 |
EP2332990A1 (en) | 2011-06-15 |
PT1735348E (en) | 2012-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2560305C (en) | Human anti-epidermal growth factor receptor antibody | |
JP6694850B2 (en) | Antibody that specifically binds to an epitope within the SEMA domain of c-Met | |
US6811779B2 (en) | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy | |
EP2764024B1 (en) | Anti c-met antibody and uses thereof | |
US9505843B2 (en) | Anti-Her3 scFV fragment and bispecific anti-c-Met/anti-Her3 antibodies comprising the same | |
US7947811B2 (en) | Antibodies that bind specifically to human RON protein | |
US20090246205A1 (en) | Inhibition of macrophage-stimulating protein receptor (ron) | |
US20090022714A1 (en) | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist | |
EP2832748B1 (en) | Anti-EGFR antibody and Anti-C-Met/Anti-EGFR bispecific antibodies comprising the same | |
US20210269533A1 (en) | Anti-c-met antibody and uses thereof | |
US10000569B2 (en) | Anti-cMet/anti-EGFR/anti-HER3 multispecific antibodies and use thereof | |
US9717715B2 (en) | Method of combination therapy using an anti-C-Met antibody | |
KR102042174B1 (en) | Humanized and affinity-matured anti c-Met antibody and uses thereof | |
WO2021013064A1 (en) | Humanized vegfr2 antibody and application thereof | |
WO2021013061A1 (en) | Humanized anti-vegfr2 antibody and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20220301 |
|
MKLA | Lapsed |
Effective date: 20200831 |